{"gene":"CD58","run_date":"2026-04-28T17:28:52","timeline":{"discoveries":[{"year":1982,"finding":"LFA-3 (CD58) is a cell surface antigen (Mr ~60,000) expressed on both B and T lymphocytes that participates in CTL-target cell interaction; monoclonal antibodies blocking LFA-3 inhibit CTL-mediated killing, with anti-LFA-3 antibodies acting on target cells rather than effectors.","method":"Monoclonal antibody inhibition of CTL killing assay (51Cr-release), immunoprecipitation, NaDodSO4/PAGE, immunofluorescence flow cytometry","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — foundational discovery replicated in multiple subsequent studies; multiple orthogonal methods","pmids":["6984191"],"is_preprint":false},{"year":1983,"finding":"LFA-3 is a widely distributed antigen (Mr 60,000) present on both hematopoietic and nonhematopoietic tissues that functions on target cells to mediate CTL-mediated cytotoxicity and T cell proliferative responses; anti-LFA-3 MAb block by binding to target cells, not effectors.","method":"Monoclonal antibody blocking of CTL killing, MLR, and PHA proliferation assays","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — replicated across multiple functional assays, consistent with founding paper","pmids":["6345670"],"is_preprint":false},{"year":1984,"finding":"LFA-3 mediates CTL-target cell conjugate formation; antibodies to LFA-3 inhibit cytolysis by blocking CTL-target cell adhesion.","method":"CTL-target conjugate formation assay, 51Cr-release cytotoxicity assay with monoclonal antibody blocking","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — direct conjugate formation assay, replicated","pmids":["6201533"],"is_preprint":false},{"year":1987,"finding":"LFA-3 (CD58) is the direct cell-surface ligand for CD2; purified CD2 binds to human erythrocyte LFA-3 and mediates adhesion, and purified CD2 inhibits T cell rosetting with erythrocytes in an LFA-3-dependent manner.","method":"Radiolabeled (125I) CD2 binding to erythrocytes, rosetting inhibition assay, purified protein binding assays","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 — direct binding with purified proteins, replicated independently","pmids":["2951597"],"is_preprint":false},{"year":1987,"finding":"LFA-3 cDNA encodes a phospholipid-linked (GPI-anchored) membrane protein whose extracellular domain shares significant homology with its receptor CD2, both being members of the immunoglobulin superfamily.","method":"cDNA cloning, sequence analysis, transient expression in mouse cells","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 — cDNA cloning with sequence-based structural analysis, foundational paper >700 citations","pmids":["3313052"],"is_preprint":false},{"year":1987,"finding":"LFA-3 exists in two distinct membrane-anchored forms derived from different biosynthetic precursors: one anchored by a phosphatidylinositol glycan (GPI) moiety and one with a conventional transmembrane segment.","method":"Phosphatidylinositol-specific phospholipase C (PIPLC) treatment, biosynthetic labeling, biochemical fractionation","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 — enzymatic treatment and biochemical fractionation demonstrating two isoforms; replicated in multiple subsequent studies","pmids":["3313053"],"is_preprint":false},{"year":1987,"finding":"LFA-3 on erythrocytes is attached to the membrane by a phosphatidylinositol glycolipid anchor; deficiency of LFA-3 on PNH erythrocytes correlates with phosphatidylinositol-anchored protein deficiency, and reconstitution of purified LFA-3 into PNH erythrocytes restores CD2 binding and rosetting activity.","method":"PIPLC treatment, 125I-CD2 binding, rosetting assay, reconstitution of purified protein into erythrocyte membranes","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 1 — reconstitution experiment plus enzymatic cleavage with functional readout","pmids":["3309123"],"is_preprint":false},{"year":1987,"finding":"CD2 and LFA-3 mediate thymocyte binding to thymic epithelial cells; anti-LFA-3 antibodies block binding when applied to thymic epithelial cells, while anti-CD2 antibodies block when applied to thymocytes, demonstrating LFA-3 on TE cells engages CD2 on thymocytes.","method":"Rosette formation inhibition assay with monoclonal antibodies, indirect immunofluorescence","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — clean dissection of receptor (CD2) vs. ligand (LFA-3) on defined cell populations, replicated","pmids":["3098838"],"is_preprint":false},{"year":1987,"finding":"LFA-3 expressed on human erythrocytes is the ligand for CD2; purified CD2 binds to erythrocyte LFA-3 and mediates T cell rosetting, with LFA-3 mAb blocking 125I-CD2 binding and CD2 blocking LFA-3 mAb binding (reciprocal competition).","method":"125I-CD2 binding competition, mAb blocking of rosetting, purified protein binding","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 1 — purified protein binding with reciprocal competition demonstrating direct interaction","pmids":["3102675"],"is_preprint":false},{"year":1988,"finding":"LFA-3 can activate T cells via the CD2 complex; purified multimeric LFA-3 combined with anti-CD2 mAb induces intracellular calcium increases, phosphatidylinositol second messenger generation, and lymphokine secretion in Jurkat cells, but only when CD3/Ti complex is expressed and functionally intact.","method":"Intracellular calcium measurement, phosphatidylinositol hydrolysis assay, lymphokine secretion, CD3-deficient Jurkat mutants with TCR beta-chain reconstitution","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — signaling assays in mutant cell lines with genetic rescue, multiple readouts","pmids":["2459194"],"is_preprint":false},{"year":1988,"finding":"LFA-3 expressed on transfected L cells costimulates T cell and thymocyte proliferation via CD2; proliferation is inhibited by anti-CD2 or anti-LFA-3 mAbs and is associated with increased IL-2R expression.","method":"L cell transfection with LFA-3 genomic DNA, T cell proliferation assay, mAb blocking, IL-2R expression analysis","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — defined transfection system with specific mAb blocking, multiple readouts","pmids":["2834437"],"is_preprint":false},{"year":1990,"finding":"Engagement of monocyte LFA-3 by immobilized anti-LFA-3 antibody or by purified CD2 (its physiologic receptor) triggers TNF-alpha and IL-1 beta release from monocytes, demonstrating that the CD2-LFA-3 receptor-ligand adhesion interaction can transmit signals inducing monokine secretion.","method":"Cytokine release assay (TNF-alpha, IL-1 beta) with immobilized antibodies and purified CD2 protein","journal":"Science","confidence":"High","confidence_rationale":"Tier 2 — purified CD2 used as physiologic ligand for LFA-3 with cytokine readout, specific functional mechanism demonstrated","pmids":["1697984"],"is_preprint":false},{"year":1990,"finding":"Binding of anti-LFA-3 mAb (monovalent Fab' fragments sufficient) to thymic epithelial cell LFA-3 augments IL-1 alpha and IL-1 beta mRNA production and protein release, requiring new protein and RNA synthesis; this signals via LFA-3 engagement during thymocyte-TE cell contact.","method":"IL-1 release assay, Northern blot, cycloheximide/actinomycin D inhibition, Fab' fragment binding","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — monovalent Fab fragments rule out crosslinking artifact; multiple molecular readouts","pmids":["1693636"],"is_preprint":false},{"year":1991,"finding":"Lateral mobility of GPI-anchored LFA-3 in the membrane enhances the rate of CD2-mediated cell adhesion strengthening compared to immobile transmembrane LFA-3; the GPI isoform supports more efficient adhesion at lower densities due to its ability to diffuse laterally and accumulate at the contact zone.","method":"Planar phospholipid bilayer reconstitution with GPI vs. transmembrane LFA-3 isoforms, static and laminar flow adhesion assays","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 1 — reconstitution of defined protein isoforms in bilayers with quantitative adhesion measurements","pmids":["1717480"],"is_preprint":false},{"year":1992,"finding":"CD59, in addition to CD58, is a physiological ligand for CD2; CD59 binds CD2 at an overlapping but nonidentical binding site to CD58 on CD2, and antibodies to CD59 inhibit CD2-dependent T cell activation.","method":"In vitro binding assay with purified CD58 and CD59, CD2+ cell binding, T cell activation in murine hybridomas expressing human CD2, competition binding","journal":"Science","confidence":"High","confidence_rationale":"Tier 1–2 — purified protein binding assays with two complementary competition approaches","pmids":["1377404"],"is_preprint":false},{"year":1992,"finding":"CD58 and CD59 molecules act synergistically (additively or synergistically) in mediating T cell adhesion and costimulating T cell activation; double transfectants expressing both CD58 and CD59 on CHO cells produce far more rosettes and T cell proliferation than either alone.","method":"CHO cell transfection with CD58 and/or CD59, rosette formation assay, T cell proliferation assay","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 — defined transfectant system, two functional readouts; single lab","pmids":["1370512"],"is_preprint":false},{"year":1993,"finding":"TCR stimulation or PMA treatment rapidly up-regulates CD2 avidity for CD58, requiring protein tyrosine kinase and protein kinase C activity, as well as the carboxyl-terminal asparagine of the CD2 cytoplasmic domain; cAMP elevation also up-regulates CD2 avidity through the same structural element.","method":"CD2+ cells binding to purified CD58, SRBC rosetting assay, inhibitors of PTK and PKC, CD2 cytoplasmic domain mutants","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — structure-function mutagenesis combined with pharmacological dissection in defined cell lines","pmids":["7681075"],"is_preprint":false},{"year":1993,"finding":"The CD58-binding site on CD2 is a charged surface area (~770 Å2) on the AGFCC'C\" face of the CD2 adhesion domain, involving residues on the F strand (Lys-82, Tyr-86), C strand (Asp-32, Lys-34), C' strand (Gln-46), FG loop, CC' loop, and C'C\" loop, as identified by NMR-guided site-directed mutagenesis.","method":"Site-directed mutagenesis combined with NMR structural data, CD58 binding functional assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — NMR structure combined with site-directed mutagenesis and functional binding validation","pmids":["7505442"],"is_preprint":false},{"year":1993,"finding":"The CD58 binding site on CD2 maps to the beta-sheet containing strands CC'C\"FG; key residues K34, E36 (C strand), R48, K49 (C' strand), K91, N92 (FG loop) are critical for CD2 interaction with both human and sheep CD58.","method":"Site-directed mutagenesis of CD2 domain 1 based on rat CD2 NMR solution structure, rosetting assay with human and sheep erythrocytes","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 1 — structure-guided mutagenesis with functional rosetting readout","pmids":["7688025"],"is_preprint":false},{"year":1994,"finding":"The CD58-binding surface on CD2 maps to the major beta-sheet face of CD58 (AGFCC'C\" sheet), involving residues on C strand (E25, K29, K30), CC' loop (K32, D33, K34), C' strand (E37), and G strand (K87); the interaction between CD2 and CD58 involves the major beta-sheet face of each adhesion domain.","method":"Site-directed mutagenesis of charged residues on CD58 predicted to be solvent-exposed, CD2 binding functional assays","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 1 — structure-guided mutagenesis of both binding partners validated functionally","pmids":["7525842"],"is_preprint":false},{"year":1994,"finding":"Ligation of B cell CD58 by CD2 (its natural T cell ligand) or by mAb provides an IL-4-dependent signal for IgE class switching and production, specifically inducing productive epsilon transcripts and IgE production in a pathway distinct from CD40-mediated isotype switching.","method":"Highly purified B cell cultures, IL-4 + anti-CD58 mAb, CD2-transfected murine T hybridoma coculture, CD40 Fc fusion protein competition, epsilon germ-line and productive transcript analysis","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — natural ligand (CD2-transfected cells) used, distinct pathway from CD40 demonstrated with multiple orthogonal methods","pmids":["7515920"],"is_preprint":false},{"year":1996,"finding":"CD2-CD58 interaction visualized directly in the contact area between T lymphoblasts and planar bilayers containing fluorescently labeled LFA-3; LFA-3 accumulates at sites of contact with half-time ~15 min; the 2D Kd for CD2/LFA-3 interaction is ~21 molecules/μm², well below physiological densities of both molecules.","method":"Fluorescence microscopy of planar phospholipid bilayers with purified fluorescent LFA-3, two-dimensional affinity measurement, lateral diffusion analysis","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 1 — direct visualization and quantitative 2D affinity measurement in defined reconstituted system","pmids":["8636222"],"is_preprint":false},{"year":1996,"finding":"CD2-CD58 interaction optimizes T cell response to IL-12; monocyte CD58 engages T cell CD2, and CHO transfectants expressing CD58 at levels comparable to monocytes (but not CD48, a lower-avidity CD2 ligand) restore IL-12 responsiveness to APC-depleted T cells.","method":"CHO transfectants expressing CD58 or CD48, APC-depleted T cell cultures, IL-12 response assay, blocking antibodies","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — defined transfectant system with CD48 negative control distinguishing CD58-specific effect","pmids":["8757306"],"is_preprint":false},{"year":1997,"finding":"CD58 (LFA-3) costimulation via CD2 preferentially induces NF-AT nuclear factor binding and IFN-gamma production in T cells; the NF-AT induced by LFA-3 is negatively regulated by B7-1 costimulation, revealing distinct transcriptional pathways for CD2-LFA-3 vs. CD28-B7-1 costimulation.","method":"Gel shift assays for NF-AT, AP-1, NF-kappaB; IL-2 promoter-luciferase reporter transfection; CHO transfectants with HLA-DR, B7-1, and/or LFA-3","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 — gel shift and reporter assays in defined transfectant system; multiple transcription factors characterized","pmids":["9032258"],"is_preprint":false},{"year":1997,"finding":"CD2-CD58 bond dynamics in contact areas are transient; fluorescence photobleaching recovery demonstrates rapid dissociation and partner exchange of CD2-CD58 bonds in the contact zone, consistent with the fast solution off-rate (>5 s-1).","method":"Fluorescence photobleaching recovery (FRAP) in T cell-planar bilayer contact zones with fluorescent CD58","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — direct real-time measurement of bond dynamics in reconstituted system","pmids":["9188475"],"is_preprint":false},{"year":1999,"finding":"Crystal structure of the CD2-binding domain of CD58 at 1.8 Å resolution reveals an Ig superfamily V-set topology sharing structural features with CD2; the highly acidic AGFCC'C\" beta-sheet surface of CD58 is the CD2-binding interface; charge complementarity rather than shape matching drives specificity.","method":"X-ray crystallography at 1.8 Å resolution of chimeric CD58, mutation mapping","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — crystal structure with mutation mapping of binding interface","pmids":["10200255"],"is_preprint":false},{"year":1999,"finding":"CD58 is constitutively expressed on the basolateral surface of intestinal epithelial cells (polarized expression) and functions as a costimulatory molecule for CD4+ T cell proliferation mediated by intestinal epithelial cells; CD58 blockade inhibits this costimulation, while CD80 and CD86 are absent.","method":"Flow cytometry, confocal microscopy, vectorial biotinylation, antibody blocking of T cell proliferation by IEC lines","journal":"Gastroenterology","confidence":"High","confidence_rationale":"Tier 2 — direct localization tied to functional consequence with specific mAb blocking","pmids":["10220497"],"is_preprint":false},{"year":2001,"finding":"CD2 Tyr86 and CD58 Lys34 form the functional hot spot of the CD2-CD58 adhesion interface; Y86A mutation reduces CD58 binding affinity ~1000-fold while Y86F has virtually no effect (hydroxyl not required), and the CD2 D31/D32 residues orient CD58 K34 for hydrophobic contact with CD2 Y86.","method":"Isothermal titration calorimetry (ITC) of CD2 alanine mutants, CD2-CD58 crystal structure analysis","journal":"Journal of molecular biology","confidence":"High","confidence_rationale":"Tier 1 — quantitative ITC of single-residue mutants combined with structural analysis","pmids":["11575926"],"is_preprint":false},{"year":2001,"finding":"Endothelial cell costimulation of T cell activation via CD58-CD2 promotes lipid raft aggregation in T cells; CD2 crosslinking promotes raft aggregation and amplifies multiple TCR downstream pathways (AP-1, NF-AT, NF-kappaB) without targeting a single distinct pathway.","method":"AP-1/NF-AT/NF-kappaB luciferase reporter assays, IL-2 secretion assay, lipid raft aggregation assay with CD2 mAb blocking","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 — lipid raft mechanism identified with CD2 mAb blocking; single lab, multiple pathways","pmids":["11591762"],"is_preprint":false},{"year":2003,"finding":"Coexpression of CD58 (or CD48) with ICAM-1 on target cells enables strong adhesion of resting NK cells even without cytokine activation; CD58 on targets engages receptors on resting NK cells to strengthen LFA-1-mediated adhesion.","method":"Drosophila cell expression system with defined ligand combinations, resting NK cell adhesion assays, inhibitors of src-family kinase and PI3K","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — defined reconstituted system with specific ligand combinations; clean dissection of receptor requirements","pmids":["12496412"],"is_preprint":false},{"year":2006,"finding":"T cell activation increases CD2 cell surface number 1.5-fold and 2D affinity for CD58 by 2.5-fold; ligation of CD2 to CD58 decreases lateral mobility of CD2 (likely via cytoskeletal immobilization), collectively enhancing avidity and T cell-APC adhesion.","method":"Quantitative CD2 site measurements, 2D affinity measurement in contact zones, lateral mobility (FRAP) of CD2 on activated T cells","journal":"ACS chemical biology","confidence":"High","confidence_rationale":"Tier 1 — quantitative biophysical measurements of 2D affinity and mobility in defined system","pmids":["17168569"],"is_preprint":false},{"year":2009,"finding":"The protective rs2300747(G) allele in the CD58 locus is associated with a dose-dependent increase in CD58 mRNA expression and enhanced function of CD4+CD25high regulatory T cells via FoxP3 upregulation, suggesting CD58 engagement of CD2 promotes Treg function.","method":"Fine mapping and resequencing, mRNA expression quantification in LCL and PBMCs, FoxP3 expression analysis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2–3 — genetic-functional correlation with mRNA and Treg functional assay; mechanism partially defined","pmids":["19237575"],"is_preprint":false},{"year":2011,"finding":"Mutations and deletions inactivate the CD58 gene in 21% of DLBCL cases, abolishing cell-surface CD58 expression; CD58 genetic inactivation co-occurs with beta2-microglobulin inactivation, enabling escape from both T cell and NK cell immune surveillance.","method":"Sequencing of CD58 gene, deletion analysis, flow cytometry for protein expression, correlation with HLA-I loss","journal":"Cancer cell","confidence":"High","confidence_rationale":"Tier 2 — direct sequencing and protein expression analysis in primary tumor samples with functional immune evasion implication","pmids":["22137796"],"is_preprint":false},{"year":2016,"finding":"CD2-CD58 interactions are required for activation of adaptive NKG2C+CD57+ NK cells in response to HCMV-infected fibroblasts; antibody blockade of CD2 or CD58 largely abolishes CD69/CD25/HLA-DR upregulation and IFN-gamma/TNF-alpha production specifically in adaptive NK cells, correlating with HCMV-induced upregulation of CD58 on infected cells.","method":"Co-culture of PBMCs with productively infected fibroblasts, blocking antibodies against CD2 and CD58, flow cytometry for activation markers, intracellular cytokine staining","journal":"European journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — specific blocking of both receptor (CD2) and ligand (CD58) with multiple functional readouts in physiologic infection model","pmids":["27469079"],"is_preprint":false},{"year":2020,"finding":"EZH2 epigenetically silences CD58 expression in B-cell lymphoma via H3K27 trimethylation of the CD58 promoter; EZH2 inhibitors (EPZ6438, GSK126) relieve this repression, restore CD58 surface expression, and enhance T and NK cell IFN-gamma production against lymphoma cells.","method":"Epigenetic library screening, EZH2 inhibitor treatment, ChIP for H3K27me3 at CD58 promoter, flow cytometry for CD58 expression, T/NK cell IFN-gamma production co-culture assay","journal":"Molecular immunology","confidence":"High","confidence_rationale":"Tier 2 — ChIP directly demonstrates H3K27me3 at CD58 promoter; functional rescue upon EZH2 inhibition with multiple orthogonal methods","pmids":["31962268"],"is_preprint":false},{"year":2020,"finding":"T-cell rosetting in Hodgkin lymphoma is established by CD2-CD58 interaction forming an immunological synapse; CD58 knockout or CD2 blockade reduces rosette formation and T-cell activation; T-cell activation additionally requires TCR-HLA-II interaction, as shown by CIITA knockout.","method":"HL cell line coculture rosetting model, CRISPR knockout of CIITA and CD58, CD2 blocking antibodies, proximity ligation assay in primary HL tissue","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — CRISPR KO of CD58 with functional rosetting and T cell activation readouts; validated in primary tissue by proximity ligation assay","pmids":["32589698"],"is_preprint":false},{"year":2022,"finding":"CD58 loss in tumor cells impairs CAR T cell function by inducing formation of suboptimal immunological synapses, reducing CAR T cell expansion, degranulation, cytokine secretion, and cytotoxicity; CD58 was identified as a top resistance gene via genome-wide CRISPR/Cas9 screen.","method":"Genome-wide CRISPR/Cas9 screen, CD58 KO validation in vitro and in vivo, immunological synapse imaging, degranulation and cytokine assays","journal":"Blood advances","confidence":"High","confidence_rationale":"Tier 2 — unbiased genome-wide CRISPR screen followed by mechanistic validation with IS imaging and multiple functional readouts","pmids":["35728062"],"is_preprint":false},{"year":2022,"finding":"PAX5 acts as a transcriptional activator of CD58 via a PAX5-driven enhancer at the CD58 locus; the PAX5 P80R mutation disrupts this enhancer, reducing CD58 expression and blinatumomab sensitivity in B-ALL.","method":"Genome-wide CRISPR screen for blinatumomab sensitivity, transcription factor CRISPR screen (1639 genes), genome editing of PAX5 P80R, ChIP/ATAC-seq for enhancer identification, patient blast validation","journal":"Science advances","confidence":"High","confidence_rationale":"Tier 2 — CRISPR screens plus genome editing with enhancer characterization and patient validation","pmids":["36516256"],"is_preprint":false},{"year":2023,"finding":"CMTM6 is critical for CD58 protein stability; CMTM6 binding determines the balance between endosomal recycling and lysosomal degradation of CD58; CD58 and PD-L1 compete for CMTM6 binding such that loss of CD58 increases PD-L1 protein stabilization (and vice versa).","method":"CRISPR-Cas9 screens, proteomics screens, co-IP of CD58 and PD-L1 with CMTM6, endosomal recycling and lysosomal degradation assays, humanized mouse models, patient melanoma scRNA-seq","journal":"Cancer cell","confidence":"High","confidence_rationale":"Tier 2 — CRISPR screen with Co-IP validation; competition between CD58 and PD-L1 for CMTM6 mechanistically established with multiple orthogonal methods","pmids":["37327789"],"is_preprint":false},{"year":2024,"finding":"CD58 inhibits JAK2/STAT1 pathway activity by activating the LYN/CD22/SHP1 axis; loss of CD58 in DLBCL leads to elevated JAK2/STAT1 activity, increased PDL1 and IDO expression, and immune evasion; combination of CD58-CD2 costimulatory signaling with anti-PDL1 or IDO inhibitor sensitizes CD58-deficient DLBCL to CAR T cell therapy.","method":"Co-IP, RNA-seq, whole-exome sequencing, scRNA-seq, DLBCL patient samples, CAR T cell co-culture functional assays, pathway inhibitor experiments","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2–3 — Co-IP and pathway analysis with functional validation; single study but multiple orthogonal approaches","pmids":["38635903"],"is_preprint":false},{"year":2024,"finding":"HSPA4 upregulation increases ALKBH5 protein stability, which in turn decreases CD58 expression in gastric cancer cells through m6A methylation regulation; this reduces CD8+ T cell cytotoxicity and activates PD1/PDL1 axis.","method":"Co-immunoprecipitation, meRIP (m6A RNA immunoprecipitation), CD8+ T cell co-culture cytotoxicity assay, HSPA4 overexpression experiments","journal":"Journal of experimental & clinical cancer research","confidence":"Medium","confidence_rationale":"Tier 2–3 — Co-IP and meRIP establishing mechanism; functional CD8+ T cell assay; single lab","pmids":["38589927"],"is_preprint":false},{"year":1993,"finding":"A soluble form of CD58 (sCD58) is present in human serum, urine, and cell line supernatants; purified sCD58 binds to CD2-positive T cells and at high concentrations inhibits rosette formation, suggesting sCD58 can act as an immunosuppressive factor by competing with membrane-bound CD58 for CD2 binding.","method":"ELISA for CD58, gel filtration, SDS-PAGE/Western blot, rosette inhibition assay with purified sCD58","journal":"European journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2–3 — purified sCD58 used in functional rosette inhibition; biochemical characterization of soluble form","pmids":["7693485"],"is_preprint":false},{"year":2015,"finding":"CD58/CD2 is the primary costimulatory pathway for CD28-negative CD8+ T cells; CD58 broadly expressed on APCs (including dendritic cells) engages CD2 to costimulate proliferation, cytokine production, and effector function of CD28-CD8+ T cells; blocking CD58 mAb greatly reduces responses to allogeneic DCs and viral antigens.","method":"mAb blocking of CD58 in CD28-CD8+ T cell stimulation assays with DCs, allogeneic and viral antigen responses, proliferation and cytokine measurements","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — defined T cell subset with specific mAb blocking, multiple functional readouts, DCs as physiological APCs","pmids":["26041540"],"is_preprint":false}],"current_model":"CD58 (LFA-3) is a GPI-anchored or transmembrane Ig superfamily glycoprotein that functions as the primary cell-surface ligand for CD2 on T and NK cells; the CD2-CD58 interaction—characterized by a charged electrostatic interface between the AGFCC'C\" beta-sheets of both proteins (hot spot: CD2 Tyr86/CD58 Lys34)—drives T cell and NK cell adhesion, immunological synapse formation, and costimulatory signaling (including NF-AT activation, TCR signal amplification via lipid raft aggregation, IL-12 responsiveness, and IgE class switching), while CD58 protein stability is regulated by CMTM6-mediated endosomal recycling, its transcription is activated by PAX5 and repressed by EZH2-mediated H3K27 trimethylation, and loss of CD58 in tumors promotes immune evasion through impaired IS formation, increased PD-L1/IDO expression via LYN/CD22/SHP1-JAK2/STAT1 signaling, and competition with PD-L1 for CMTM6 binding."},"narrative":{"teleology":[{"year":1982,"claim":"Identification of LFA-3 (CD58) as a target-cell surface molecule required for CTL-mediated killing established its fundamental role in immune cell–cell interaction, answering whether a distinct non-MHC target-cell antigen participates in cytolysis.","evidence":"Monoclonal antibody blocking of CTL killing (51Cr-release), immunoprecipitation, and flow cytometry on B and T lymphocytes","pmids":["6984191","6345670"],"confidence":"High","gaps":["Identity of the counter-receptor on effector cells unknown","Molecular nature of LFA-3 undefined","Mechanism of action (adhesion vs. signaling) unresolved"]},{"year":1984,"claim":"Demonstration that anti-LFA-3 antibodies block CTL–target conjugate formation resolved that LFA-3 functions at the adhesion step rather than a post-adhesion lytic step.","evidence":"CTL–target conjugate formation assay with mAb blocking","pmids":["6201533"],"confidence":"High","gaps":["Counter-receptor identity still unknown","Contribution of LFA-3 to non-CTL immune interactions untested"]},{"year":1987,"claim":"Identification of CD2 as the direct receptor for CD58 using purified proteins, and molecular cloning revealing CD58 as an Ig superfamily member with both GPI-anchored and transmembrane isoforms, established the molecular framework for the CD2–CD58 adhesion system.","evidence":"Radiolabeled purified CD2 binding to erythrocyte LFA-3, cDNA cloning with sequence analysis, PIPLC enzymatic treatment distinguishing two anchor forms, reconstitution of purified LFA-3 into PNH erythrocytes restoring rosetting","pmids":["2951597","3313052","3313053","3309123"],"confidence":"High","gaps":["Structural basis of CD2–CD58 interaction unknown","Functional significance of two isoforms unclear","Signaling consequences of engagement undefined"]},{"year":1988,"claim":"Demonstration that LFA-3 engagement of CD2 triggers calcium flux, phosphatidylinositol hydrolysis, and T cell proliferation—requiring an intact CD3/TCR complex—established CD58 as a bona fide costimulatory molecule rather than a simple adhesion factor.","evidence":"Signaling assays in Jurkat cells and CD3-deficient mutants with reconstitution; L cell transfectants driving T cell proliferation blocked by anti-CD2/anti-LFA-3 mAbs","pmids":["2459194","2834437"],"confidence":"High","gaps":["Downstream transcription factor targets uncharacterized","Whether CD58 itself transduces signals (reverse signaling) unknown"]},{"year":1990,"claim":"Discovery that CD2 engagement of LFA-3 on monocytes and thymic epithelial cells triggers TNF-α, IL-1α, and IL-1β release established bidirectional signaling through the CD2–CD58 axis—CD58 is not merely a passive ligand.","evidence":"Cytokine release assays with immobilized anti-LFA-3 and purified CD2 on monocytes; monovalent Fab′ fragment stimulation of thymic epithelial cells with actinomycin D/cycloheximide controls","pmids":["1697984","1693636"],"confidence":"High","gaps":["CD58 reverse signaling pathway components undefined","Whether GPI-anchored isoform can signal remains unresolved"]},{"year":1991,"claim":"Reconstitution of GPI-anchored versus transmembrane CD58 in planar bilayers showed that the GPI isoform's greater lateral mobility accelerates adhesion strengthening, providing a functional rationale for the two isoforms.","evidence":"Planar phospholipid bilayer reconstitution with purified isoforms, static and laminar flow adhesion assays","pmids":["1717480"],"confidence":"High","gaps":["In vivo relevance of isoform-specific adhesion kinetics untested","Regulation of isoform expression across tissues unknown"]},{"year":1993,"claim":"NMR-guided and structure-based mutagenesis of both CD2 and CD58 mapped the binding interface to the AGFCC′C″ beta-sheet face of each domain, identifying key charged residues and establishing the electrostatic nature of the interaction.","evidence":"Site-directed mutagenesis guided by NMR structure of CD2, functional rosetting and binding assays for CD2 and CD58 mutants","pmids":["7505442","7688025"],"confidence":"High","gaps":["No co-crystal structure yet","Energetic contribution of individual residues not quantified"]},{"year":1994,"claim":"Mapping the CD58-side interface and demonstrating that CD58 ligation on B cells induces IL-4-dependent IgE class switching (distinct from CD40 pathway) broadened CD58's role beyond T cell adhesion to include B cell isotype regulation.","evidence":"CD58 mutagenesis with CD2-binding assays; purified B cell cultures with anti-CD58 mAb or CD2-transfected hybridomas, epsilon transcript analysis","pmids":["7525842","7515920"],"confidence":"High","gaps":["Signaling pathway from CD58 to epsilon germline transcription unknown","In vivo relevance of CD58-driven IgE switching unconfirmed"]},{"year":1996,"claim":"Direct visualization of CD58 accumulation at T cell contact sites and measurement of a 2D Kd (~21 molecules/μm²) well below physiological densities, combined with the finding that CD58 optimizes T cell IL-12 responsiveness, established the biophysical basis for efficient synapse-like contact formation.","evidence":"Fluorescence microscopy of planar bilayers with fluorescent LFA-3; CHO transfectants expressing CD58 vs. CD48 in APC-depleted T cell IL-12 response assays","pmids":["8636222","8757306"],"confidence":"High","gaps":["True immunological synapse architecture with CD58 not yet characterized","Whether CD58 segregates into distinct synapse zones unknown"]},{"year":1999,"claim":"The 1.8 Å crystal structure of the CD58 adhesion domain confirmed the V-set Ig topology and revealed that charge complementarity rather than shape matching drives CD2 binding specificity, resolving the structural basis of the interaction.","evidence":"X-ray crystallography of chimeric CD58 with mutation mapping","pmids":["10200255"],"confidence":"High","gaps":["Co-crystal of the CD2–CD58 complex not yet solved","How charge complementarity translates to fast kinetics not mechanistically explained"]},{"year":2001,"claim":"Identification of the CD2 Tyr86–CD58 Lys34 hot spot by ITC of alanine mutants quantified the energetic architecture of the interface and showed that CD58 costimulation promotes lipid raft aggregation as a mechanism of TCR signal amplification.","evidence":"Isothermal titration calorimetry of single-residue CD2 mutants; luciferase reporter assays for AP-1/NF-AT/NF-κB with lipid raft aggregation measurement on endothelial cell costimulation","pmids":["11575926","11591762"],"confidence":"High","gaps":["Raft aggregation mechanism downstream of CD2 undefined","Whether raft mechanism applies in vivo during APC encounter unknown"]},{"year":2011,"claim":"Discovery that CD58 is genetically inactivated (mutations/deletions) in 21% of DLBCLs, co-occurring with β2-microglobulin loss, established CD58 as a tumor suppressor whose loss enables dual escape from T and NK cell surveillance.","evidence":"Sequencing and deletion analysis of CD58 in primary DLBCL samples, flow cytometry for surface expression, correlation with HLA-I loss","pmids":["22137796"],"confidence":"High","gaps":["Functional immune evasion not directly demonstrated in these tumors","Whether CD58 loss is a driver or passenger event unresolved"]},{"year":2015,"claim":"Establishing CD58–CD2 as the primary costimulatory pathway for CD28-negative CD8+ T cells explained how terminally differentiated effector cells maintain responsiveness in the absence of classical costimulation.","evidence":"mAb blocking of CD58 in DC-stimulated CD28⁻CD8⁺ T cell assays measuring proliferation, cytokines, and responses to viral antigens","pmids":["26041540"],"confidence":"High","gaps":["Molecular basis for CD58 dominance over other CD2 ligands (CD48, CD59) in this context unexplored","In vivo validation lacking"]},{"year":2020,"claim":"Demonstration that EZH2 silences CD58 via H3K27me3 at its promoter, and that CD58 knockout disrupts T cell rosetting in Hodgkin lymphoma requiring both CD58-CD2 and TCR-HLA-II interactions, linked epigenetic regulation to immunological synapse integrity.","evidence":"ChIP for H3K27me3 at CD58 promoter with EZH2 inhibitor rescue; CRISPR KO of CD58 in HL cell lines with rosetting and proximity ligation in primary tissue","pmids":["31962268","32589698"],"confidence":"High","gaps":["Whether EZH2-mediated silencing is specific to lymphoma or occurs broadly untested","Precise structure of CD58-dependent immunological synapse undefined"]},{"year":2022,"claim":"Genome-wide CRISPR screens identified CD58 as a top resistance gene for CAR T cell therapy and PAX5 as a transcriptional activator of CD58 via an enhancer element, mechanistically connecting transcription factor mutations to immune evasion.","evidence":"CRISPR screens for CAR T cell and blinatumomab sensitivity; CD58 KO with IS imaging and functional validation; PAX5 P80R genome editing with ChIP/ATAC-seq for enhancer characterization","pmids":["35728062","36516256"],"confidence":"High","gaps":["Whether restoring CD58 expression rescues CAR T resistance in vivo untested","Full catalog of transcription factors regulating CD58 incomplete"]},{"year":2023,"claim":"Discovery that CMTM6 stabilizes CD58 through endosomal recycling, and that CD58 and PD-L1 compete for CMTM6 binding, revealed a post-translational regulatory axis linking loss of one immune molecule to gain of another inhibitory checkpoint.","evidence":"CRISPR screens, proteomics, co-IP of CD58/PD-L1 with CMTM6, endosomal recycling and lysosomal degradation assays, humanized mouse models, patient melanoma scRNA-seq","pmids":["37327789"],"confidence":"High","gaps":["Structural basis of CMTM6 selectivity between CD58 and PD-L1 unknown","Whether CMTM6 competition is therapeutically targetable untested","Stoichiometry of the CD58–CMTM6 complex undefined"]},{"year":2024,"claim":"Identification of the LYN/CD22/SHP1 axis as CD58's mechanism for suppressing JAK2/STAT1 signaling—and showing that CD58 loss derepresses PD-L1 and IDO expression—provided a signaling pathway linking CD58 to immune checkpoint regulation beyond simple adhesion.","evidence":"Co-IP, RNA-seq, whole-exome sequencing, scRNA-seq in DLBCL patient samples, CAR T cell co-culture with pathway inhibitors","pmids":["38635903"],"confidence":"Medium","gaps":["LYN/CD22/SHP1 pathway downstream of CD58 established in single study","Whether this signaling axis operates in non-lymphoma contexts untested","Direct physical interaction between CD58 and LYN not demonstrated"]},{"year":null,"claim":"Key unresolved questions include the atomic structure of the CD2–CD58 complex, the structural basis for CMTM6 selectivity between CD58 and PD-L1, whether therapeutic restoration of CD58 expression can overcome immune evasion in vivo, and the full signaling cascade downstream of CD58 reverse signaling in non-lymphoid cells.","evidence":"","pmids":[],"confidence":"Low","gaps":["No CD2–CD58 co-crystal structure","CD58 reverse signaling pathway largely undefined","Therapeutic strategies to restore CD58 not clinically validated"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098631","term_label":"cell adhesion mediator activity","supporting_discovery_ids":[0,2,3,13,21,29]},{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[3,8,9,10,22,42]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,4,5,6,26]}],"pathway":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[41]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[9,10,22,23,33,42]},{"term_id":"R-HSA-1500931","term_label":"Cell-Cell communication","supporting_discovery_ids":[2,7,13,21,35,36]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[23,28,39]}],"complexes":[],"partners":["CD2","CMTM6","PAX5","EZH2","CD59","LYN","ALKBH5"],"other_free_text":[]},"mechanistic_narrative":"CD58 (LFA-3) is an immunoglobulin superfamily glycoprotein that serves as the principal ligand for CD2 on T cells and NK cells, mediating intercellular adhesion, immunological synapse formation, and costimulatory signaling essential for adaptive and innate immune responses [PMID:2951597, PMID:6984191, PMID:12496412]. CD58 exists as GPI-anchored and transmembrane isoforms, with the GPI form exhibiting enhanced lateral mobility that accelerates adhesion strengthening; the CD2–CD58 interaction is driven by charge complementarity between the AGFCC′C″ beta-sheet faces of both proteins, centered on a hot spot involving CD2 Tyr86 and CD58 Lys34 [PMID:3313053, PMID:10200255, PMID:11575926]. Engagement of CD58 costimulates T cell activation through NF-AT induction, lipid raft aggregation, and TCR signal amplification, promotes IL-12 responsiveness, drives IgE class switching on B cells, and triggers monokine release from monocytes and epithelial cells [PMID:9032258, PMID:11591762, PMID:8757306, PMID:7515920, PMID:1697984]. CD58 protein stability is regulated by CMTM6-mediated endosomal recycling in competition with PD-L1, its transcription is activated by PAX5 and repressed by EZH2-catalyzed H3K27 trimethylation, and loss of CD58—occurring in ~21% of DLBCLs—promotes immune evasion through impaired synapse formation and upregulation of PD-L1/IDO via derepressed JAK2/STAT1 signaling [PMID:37327789, PMID:36516256, PMID:31962268, PMID:22137796, PMID:38635903]."},"prefetch_data":{"uniprot":{"accession":"P19256","full_name":"Lymphocyte function-associated antigen 3","aliases":["Surface glycoprotein LFA-3"],"length_aa":250,"mass_kda":28.1,"function":"Ligand of the T-lymphocyte CD2 glycoprotein. This interaction is important in mediating thymocyte interactions with thymic epithelial cells, antigen-independent and -dependent interactions of T-lymphocytes with target cells and antigen-presenting cells and the T-lymphocyte rosetting with erythrocytes. In addition, the LFA-3/CD2 interaction may prime response by both the CD2+ and LFA-3+ cells","subcellular_location":"Cell membrane","url":"https://www.uniprot.org/uniprotkb/P19256/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CD58","classification":"Not Classified","n_dependent_lines":15,"n_total_lines":1208,"dependency_fraction":0.012417218543046357},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CD58","total_profiled":1310},"omim":[{"mim_id":"614711","title":"FAMILY WITH SEQUENCE SIMILARITY 72, MEMBER B; FAM72B","url":"https://www.omim.org/entry/614711"},{"mim_id":"606620","title":"SLAM FAMILY, MEMBER 8; SLAMF8","url":"https://www.omim.org/entry/606620"},{"mim_id":"604516","title":"IMMUNOGLOBULIN SUPERFAMILY, MEMBER 2; IGSF2","url":"https://www.omim.org/entry/604516"},{"mim_id":"604470","title":"CD2 ANTIGEN-BINDING PROTEIN 2; CD2BP2","url":"https://www.omim.org/entry/604470"},{"mim_id":"602069","title":"NEUROPILIN 1; NRP1","url":"https://www.omim.org/entry/602069"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/CD58"},"hgnc":{"alias_symbol":[],"prev_symbol":["LFA3"]},"alphafold":{"accession":"P19256","domains":[{"cath_id":"2.60.40.10","chopping":"28-122","consensus_level":"high","plddt":92.9606,"start":28,"end":122},{"cath_id":"2.60.40,2.60.40","chopping":"129-206","consensus_level":"high","plddt":92.3354,"start":129,"end":206}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P19256","model_url":"https://alphafold.ebi.ac.uk/files/AF-P19256-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P19256-F1-predicted_aligned_error_v6.png","plddt_mean":82.94},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CD58","jax_strain_url":"https://www.jax.org/strain/search?query=CD58"},"sequence":{"accession":"P19256","fasta_url":"https://rest.uniprot.org/uniprotkb/P19256.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P19256/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P19256"}},"corpus_meta":[{"pmid":"6984191","id":"PMC_6984191","title":"Three distinct antigens associated with human T-lymphocyte-mediated cytolysis: LFA-1, LFA-2, and LFA-3.","date":"1982","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/6984191","citation_count":884,"is_preprint":false},{"pmid":"3313052","id":"PMC_3313052","title":"An LFA-3 cDNA encodes a phospholipid-linked membrane protein homologous to its receptor CD2.","date":"1987","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/3313052","citation_count":742,"is_preprint":false},{"pmid":"6345670","id":"PMC_6345670","title":"The functional significance, distribution, and structure of LFA-1, LFA-2, and LFA-3: cell surface antigens associated with CTL-target interactions.","date":"1983","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/6345670","citation_count":694,"is_preprint":false},{"pmid":"2951597","id":"PMC_2951597","title":"The T lymphocyte glycoprotein CD2 binds the cell surface ligand LFA-3.","date":"1987","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/2951597","citation_count":520,"is_preprint":false},{"pmid":"1372018","id":"PMC_1372018","title":"Differential costimulatory effects of adhesion molecules B7, ICAM-1, LFA-3, and VCAM-1 on resting and antigen-primed CD4+ T lymphocytes.","date":"1992","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/1372018","citation_count":455,"is_preprint":false},{"pmid":"22137796","id":"PMC_22137796","title":"Combined genetic inactivation of β2-Microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma.","date":"2011","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/22137796","citation_count":372,"is_preprint":false},{"pmid":"1697984","id":"PMC_1697984","title":"LFA-3, CD44, and CD45: physiologic triggers of human monocyte TNF and IL-1 release.","date":"1990","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/1697984","citation_count":318,"is_preprint":false},{"pmid":"19898481","id":"PMC_19898481","title":"Genetic variants at CD28, PRDM1 and CD2/CD58 are associated with rheumatoid arthritis risk.","date":"2009","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19898481","citation_count":284,"is_preprint":false},{"pmid":"6201533","id":"PMC_6201533","title":"LFA-1, LFA-2, and LFA-3 antigens are involved in CTL-target conjugation.","date":"1984","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/6201533","citation_count":266,"is_preprint":false},{"pmid":"3098838","id":"PMC_3098838","title":"Thymocyte binding to human thymic epithelial cells is inhibited by monoclonal antibodies to CD-2 and LFA-3 antigens.","date":"1987","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/3098838","citation_count":253,"is_preprint":false},{"pmid":"3313053","id":"PMC_3313053","title":"Anchoring mechanisms for LFA-3 cell adhesion glycoprotein at membrane surface.","date":"1987","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/3313053","citation_count":238,"is_preprint":false},{"pmid":"8636222","id":"PMC_8636222","title":"Visualization of CD2 interaction with LFA-3 and determination of the two-dimensional dissociation constant for adhesion receptors in a contact area.","date":"1996","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/8636222","citation_count":191,"is_preprint":false},{"pmid":"1377404","id":"PMC_1377404","title":"Overlapping but nonidentical binding sites on CD2 for CD58 and a second ligand CD59.","date":"1992","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/1377404","citation_count":179,"is_preprint":false},{"pmid":"1717480","id":"PMC_1717480","title":"Influence of receptor lateral mobility on adhesion strengthening between membranes containing LFA-3 and CD2.","date":"1991","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/1717480","citation_count":173,"is_preprint":false},{"pmid":"10517495","id":"PMC_10517495","title":"Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu.","date":"1999","source":"Experimental hematology","url":"https://pubmed.ncbi.nlm.nih.gov/10517495","citation_count":171,"is_preprint":false},{"pmid":"3309123","id":"PMC_3309123","title":"Deficiency of lymphocyte function-associated antigen 3 (LFA-3) in paroxysmal nocturnal hemoglobinuria. Functional correlates and evidence for a phosphatidylinositol membrane anchor.","date":"1987","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/3309123","citation_count":152,"is_preprint":false},{"pmid":"19237575","id":"PMC_19237575","title":"The role of the CD58 locus in multiple sclerosis.","date":"2009","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/19237575","citation_count":148,"is_preprint":false},{"pmid":"3102675","id":"PMC_3102675","title":"Rosetting of activated human T lymphocytes with autologous erythrocytes. Definition of the receptor and ligand molecules as CD2 and lymphocyte function-associated antigen 3 (LFA-3).","date":"1987","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/3102675","citation_count":148,"is_preprint":false},{"pmid":"2459194","id":"PMC_2459194","title":"The CD2 ligand LFA-3 activates T cells but depends on the expression and function of the antigen receptor.","date":"1988","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/2459194","citation_count":147,"is_preprint":false},{"pmid":"2459196","id":"PMC_2459196","title":"Triggering of co-mitogenic signals in T cell proliferation by anti-LFA-1 (CD18, CD11a), LFA-3, and CD7 monoclonal antibodies.","date":"1988","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/2459196","citation_count":143,"is_preprint":false},{"pmid":"8834450","id":"PMC_8834450","title":"T cell activation pathways: B7, LFA-3, and ICAM-1 shape unique T cell profiles.","date":"1995","source":"Critical reviews in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/8834450","citation_count":128,"is_preprint":false},{"pmid":"7686816","id":"PMC_7686816","title":"Differential expression of cell adhesion molecules CD54/CD11a and CD58/CD2 by human melanoma cells and functional role in their interaction with cytotoxic cells.","date":"1993","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/7686816","citation_count":122,"is_preprint":false},{"pmid":"18650830","id":"PMC_18650830","title":"Replication of KIAA0350, IL2RA, RPL5 and CD58 as multiple sclerosis susceptibility genes in Australians.","date":"2008","source":"Genes and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/18650830","citation_count":106,"is_preprint":false},{"pmid":"1693656","id":"PMC_1693656","title":"Structure, expression, and genetic linkage of the mouse BCM1 (OX45 or Blast-1) antigen. Evidence for genetic duplication giving rise to the BCM1 region on mouse chromosome 1 and the CD2/LFA3 region on mouse chromosome 3.","date":"1990","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/1693656","citation_count":103,"is_preprint":false},{"pmid":"2834437","id":"PMC_2834437","title":"Interaction of CD2 with its ligand, LFA-3, in human T cell proliferation.","date":"1988","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/2834437","citation_count":103,"is_preprint":false},{"pmid":"7682988","id":"PMC_7682988","title":"Up-regulation of LFA-3 and ICAM-1 on the surface of fibroblasts infected with cytomegalovirus.","date":"1993","source":"Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/7682988","citation_count":89,"is_preprint":false},{"pmid":"7505442","id":"PMC_7505442","title":"The CD58 (LFA-3) binding site is a localized and highly charged surface area on the AGFCC'C\" face of the human CD2 adhesion domain.","date":"1993","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/7505442","citation_count":86,"is_preprint":false},{"pmid":"26041540","id":"PMC_26041540","title":"CD58/CD2 Is the Primary Costimulatory Pathway in Human CD28-CD8+ T Cells.","date":"2015","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/26041540","citation_count":83,"is_preprint":false},{"pmid":"1370512","id":"PMC_1370512","title":"CD58 and CD59 molecules exhibit potentializing effects in T cell adhesion and activation.","date":"1992","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/1370512","citation_count":83,"is_preprint":false},{"pmid":"2466936","id":"PMC_2466936","title":"Blast-1 possesses a glycosyl-phosphatidylinositol (GPI) membrane anchor, is related to LFA-3 and OX-45, and maps to chromosome 1q21-23.","date":"1989","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/2466936","citation_count":77,"is_preprint":false},{"pmid":"1382543","id":"PMC_1382543","title":"Expression of adhesion molecules LFA-3 and N-CAM on normal and malignant human plasma cells.","date":"1992","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/1382543","citation_count":75,"is_preprint":false},{"pmid":"12496412","id":"PMC_12496412","title":"Coexpression of CD58 or CD48 with intercellular adhesion molecule 1 on target cells enhances adhesion of resting NK cells.","date":"2003","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/12496412","citation_count":72,"is_preprint":false},{"pmid":"8757306","id":"PMC_8757306","title":"Molecular interaction between CD58 and CD2 counter-receptors mediates the ability of monocytes to augment T cell activation by IL-12.","date":"1996","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/8757306","citation_count":71,"is_preprint":false},{"pmid":"8900310","id":"PMC_8900310","title":"Cytomegalovirus induced up-regulation of LFA-3 (CD58) and ICAM-1 (CD54) is a direct viral effect that is not prevented by ganciclovir or foscarnet treatment.","date":"1996","source":"Transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/8900310","citation_count":70,"is_preprint":false},{"pmid":"1693636","id":"PMC_1693636","title":"Ligand binding to the LFA-3 cell adhesion molecule induces IL-1 production by human thymic epithelial cells.","date":"1990","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/1693636","citation_count":70,"is_preprint":false},{"pmid":"1379302","id":"PMC_1379302","title":"Distribution of ICAM-1, LFA-3 and HLA-DR in healthy and diseased gingival tissues.","date":"1992","source":"Journal of periodontal research","url":"https://pubmed.ncbi.nlm.nih.gov/1379302","citation_count":68,"is_preprint":false},{"pmid":"37327789","id":"PMC_37327789","title":"The CD58-CD2 axis is co-regulated with PD-L1 via CMTM6 and shapes anti-tumor immunity.","date":"2023","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/37327789","citation_count":66,"is_preprint":false},{"pmid":"1721039","id":"PMC_1721039","title":"New monoclonal antibodies in CD44 and CD58: their use to quantify CD44 and CD58 on normal human erythrocytes and to compare the distribution of CD44 and CD58 in human tissues.","date":"1991","source":"Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/1721039","citation_count":65,"is_preprint":false},{"pmid":"14607753","id":"PMC_14607753","title":"Expression of CD58 in normal, regenerating and leukemic bone marrow B cells: implications for the detection of minimal residual disease in acute lymphocytic leukemia.","date":"2003","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/14607753","citation_count":63,"is_preprint":false},{"pmid":"34168659","id":"PMC_34168659","title":"CD58 Immunobiology at a Glance.","date":"2021","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/34168659","citation_count":61,"is_preprint":false},{"pmid":"27469079","id":"PMC_27469079","title":"CD2-CD58 interactions are pivotal for the activation and function of adaptive natural killer cells in human cytomegalovirus infection.","date":"2016","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/27469079","citation_count":60,"is_preprint":false},{"pmid":"9188475","id":"PMC_9188475","title":"Adhesive bond dynamics in contacts between T lymphocytes and glass-supported planar bilayers reconstituted with the immunoglobulin-related adhesion molecule CD58.","date":"1997","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9188475","citation_count":58,"is_preprint":false},{"pmid":"1706327","id":"PMC_1706327","title":"The high lysability by LAK cells of colon-carcinoma cells resistant to doxorubicin is associated with a high expression of ICAM-1, LFA-3, NCA and a less-differentiated phenotype.","date":"1991","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/1706327","citation_count":57,"is_preprint":false},{"pmid":"1371132","id":"PMC_1371132","title":"Stimulation of human monocytes via CD45, CD44, and LFA-3 triggers macrophage-colony-stimulating factor production. Synergism with lipopolysaccharide and IL-1 beta.","date":"1992","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/1371132","citation_count":56,"is_preprint":false},{"pmid":"1691936","id":"PMC_1691936","title":"Low expression of lymphocyte function-associated antigen (LFA)-1 and LFA-3 adhesion molecules is a common trait in Burkitt's lymphoma associated with and not associated with Epstein-Barr virus.","date":"1990","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/1691936","citation_count":55,"is_preprint":false},{"pmid":"7686194","id":"PMC_7686194","title":"Immune modulation of adhesion molecules ICAM-1 (CD54) and LFA-3 (CD58) in human hepatocytic cell lines.","date":"1993","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/7686194","citation_count":54,"is_preprint":false},{"pmid":"8992978","id":"PMC_8992978","title":"The role of B7-1 and LFA-3 in costimulation of CD8+ T cells.","date":"1997","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/8992978","citation_count":54,"is_preprint":false},{"pmid":"1704356","id":"PMC_1704356","title":"Target lysis by human LAK cells is critically dependent upon target binding properties, but LFA-1, LFA-3 and ICAM-1 are not the major adhesion ligands on targets.","date":"1991","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/1704356","citation_count":54,"is_preprint":false},{"pmid":"10200255","id":"PMC_10200255","title":"Crystal structure of the CD2-binding domain of CD58 (lymphocyte function-associated antigen 3) at 1.8-A resolution.","date":"1999","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/10200255","citation_count":52,"is_preprint":false},{"pmid":"35728062","id":"PMC_35728062","title":"CD58 loss in tumor cells confers functional impairment of CAR T cells.","date":"2022","source":"Blood advances","url":"https://pubmed.ncbi.nlm.nih.gov/35728062","citation_count":51,"is_preprint":false},{"pmid":"7515920","id":"PMC_7515920","title":"CD58 (LFA-3) stimulation provides a signal for human isotype switching and IgE production distinct from CD40.","date":"1994","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/7515920","citation_count":50,"is_preprint":false},{"pmid":"35881486","id":"PMC_35881486","title":"Multidimensional single-cell analysis identifies a role for CD2-CD58 interactions in clinical antitumor T cell responses.","date":"2022","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/35881486","citation_count":48,"is_preprint":false},{"pmid":"11258789","id":"PMC_11258789","title":"CD58/LFA-3 and IL-12 provided by activated monocytes are critical in the in vitro expansion of CD56+ T cells.","date":"2001","source":"Cancer immunology, immunotherapy : CII","url":"https://pubmed.ncbi.nlm.nih.gov/11258789","citation_count":48,"is_preprint":false},{"pmid":"7688025","id":"PMC_7688025","title":"Mutational analysis of the CD2/CD58 interaction: the binding site for CD58 lies on one face of the first domain of human CD2.","date":"1993","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/7688025","citation_count":47,"is_preprint":false},{"pmid":"12668431","id":"PMC_12668431","title":"Forced detachment of the CD2-CD58 complex.","date":"2003","source":"Biophysical journal","url":"https://pubmed.ncbi.nlm.nih.gov/12668431","citation_count":45,"is_preprint":false},{"pmid":"7681075","id":"PMC_7681075","title":"Signal transduction pathways involved in T cell receptor-induced regulation of CD2 avidity for CD58.","date":"1993","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/7681075","citation_count":43,"is_preprint":false},{"pmid":"32589698","id":"PMC_32589698","title":"Rosetting T cells in Hodgkin lymphoma are activated by immunological synapse components HLA class II and CD58.","date":"2020","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/32589698","citation_count":43,"is_preprint":false},{"pmid":"1699592","id":"PMC_1699592","title":"Selective and non-selective loss of immunoregulatory molecules (HLA-A,B,C antigens and LFA-3) in transitional cell carcinoma.","date":"1990","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/1699592","citation_count":43,"is_preprint":false},{"pmid":"7525842","id":"PMC_7525842","title":"Interaction between human CD2 and CD58 involves the major beta sheet surface of each of their respective adhesion domains.","date":"1994","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/7525842","citation_count":43,"is_preprint":false},{"pmid":"27467287","id":"PMC_27467287","title":"CD58 mutations are common in Hodgkin lymphoma cell lines and loss of CD58 expression in tumor cells occurs in Hodgkin lymphoma patients who relapse.","date":"2016","source":"Genes and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/27467287","citation_count":40,"is_preprint":false},{"pmid":"1385151","id":"PMC_1385151","title":"Structural and functional epitopes of the human adhesion receptor CD58 (LFA-3).","date":"1992","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/1385151","citation_count":39,"is_preprint":false},{"pmid":"11591762","id":"PMC_11591762","title":"Endothelial cell costimulation of T cell activation through CD58-CD2 interactions involves lipid raft aggregation.","date":"2001","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/11591762","citation_count":39,"is_preprint":false},{"pmid":"17168569","id":"PMC_17168569","title":"Mechanisms of Cellular Avidity Regulation in CD2-CD58-Mediated T Cell Adhesion.","date":"2006","source":"ACS chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/17168569","citation_count":39,"is_preprint":false},{"pmid":"8760789","id":"PMC_8760789","title":"Histamine selectively enhances human immunoglobulin E (IgE) and IgG4 production induced by anti-CD58 monoclonal antibody.","date":"1996","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/8760789","citation_count":39,"is_preprint":false},{"pmid":"11575926","id":"PMC_11575926","title":"Molecular dissection of the CD2-CD58 counter-receptor interface identifies CD2 Tyr86 and CD58 Lys34 residues as the functional \"hot spot\".","date":"2001","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/11575926","citation_count":39,"is_preprint":false},{"pmid":"1372880","id":"PMC_1372880","title":"Elevated expression of ICAM1 (CD54) and minimal expression of LFA3 (CD58) in Epstein-Barr-virus-positive nasopharyngeal carcinoma cells.","date":"1992","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/1372880","citation_count":37,"is_preprint":false},{"pmid":"2459195","id":"PMC_2459195","title":"Role of the LFA3-CD2 interaction in human specific B cell differentiation.","date":"1988","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/2459195","citation_count":36,"is_preprint":false},{"pmid":"7693485","id":"PMC_7693485","title":"A soluble form of the adhesion receptor CD58 (LFA-3) is present in human body fluids.","date":"1993","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/7693485","citation_count":36,"is_preprint":false},{"pmid":"26194173","id":"PMC_26194173","title":"Alterations of the CD58 gene in classical Hodgkin lymphoma.","date":"2015","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/26194173","citation_count":34,"is_preprint":false},{"pmid":"1717493","id":"PMC_1717493","title":"Motility and ultrastructure of large granular lymphocytes on lipid bilayers reconstituted with adhesion receptors LFA-1, ICAM-1, and two isoforms of LFA-3.","date":"1991","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/1717493","citation_count":34,"is_preprint":false},{"pmid":"27337048","id":"PMC_27337048","title":"Constrained Cyclic Peptides as Immunomodulatory Inhibitors of the CD2:CD58 Protein-Protein Interaction.","date":"2016","source":"ACS chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/27337048","citation_count":33,"is_preprint":false},{"pmid":"7521361","id":"PMC_7521361","title":"CD59 costimulation of T cell activation. CD58 dependence and requirement for glycosylation.","date":"1994","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/7521361","citation_count":33,"is_preprint":false},{"pmid":"31962268","id":"PMC_31962268","title":"EZH2 inhibitors restore epigenetically silenced CD58 expression in B-cell lymphomas.","date":"2020","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31962268","citation_count":32,"is_preprint":false},{"pmid":"10220497","id":"PMC_10220497","title":"Polarized expression and function of the costimulatory molecule CD58 on human intestinal epithelial cells.","date":"1999","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/10220497","citation_count":31,"is_preprint":false},{"pmid":"30763849","id":"PMC_30763849","title":"Decreased erythrocyte CD44 and CD58 expression link e-waste Pb toxicity to changes in erythrocyte immunity in preschool children.","date":"2019","source":"The Science of the total environment","url":"https://pubmed.ncbi.nlm.nih.gov/30763849","citation_count":30,"is_preprint":false},{"pmid":"29904386","id":"PMC_29904386","title":"Costimulatory Function of Cd58/Cd2 Interaction in Adaptive Humoral Immunity in a Zebrafish Model.","date":"2018","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/29904386","citation_count":30,"is_preprint":false},{"pmid":"3871102","id":"PMC_3871102","title":"Functional distinctions between the LFA-1, LFA-2, and LFA-3 membrane proteins on human CTL are revealed with trypsin-pretreated target cells.","date":"1985","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/3871102","citation_count":30,"is_preprint":false},{"pmid":"9032258","id":"PMC_9032258","title":"Costimulation by B7-1 and LFA-3 targets distinct nuclear factors that bind to the interleukin-2 promoter: B7-1 negatively regulates LFA-3-induced NF-AT DNA binding.","date":"1997","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/9032258","citation_count":29,"is_preprint":false},{"pmid":"8656013","id":"PMC_8656013","title":"Engagement of adhesion molecules (CD18, CD11a, CD45, CD44, and CD58) enhances human immunodeficiency virus type 1 replication in monocytic cells through a tumor necrosis factor-modulated pathway.","date":"1996","source":"The Journal of infectious diseases","url":"https://pubmed.ncbi.nlm.nih.gov/8656013","citation_count":28,"is_preprint":false},{"pmid":"1380180","id":"PMC_1380180","title":"The LFA-3 adhesion pathway is differently utilized by superantigen-activated human CD4+ T-cell subsets.","date":"1992","source":"Scandinavian journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/1380180","citation_count":27,"is_preprint":false},{"pmid":"7525717","id":"PMC_7525717","title":"Polyclonal B cell activation induced by herpesvirus saimiri-transformed human CD4+ T cell clones. Role for membrane TNF-alpha/TNF-alpha receptors and CD2/CD58 interactions.","date":"1994","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/7525717","citation_count":27,"is_preprint":false},{"pmid":"7495758","id":"PMC_7495758","title":"The primary alloresponse of human CD4+ T cells is dependent on B7 (CD80), augmented by CD58, but relatively uninfluenced by CD54 expression.","date":"1995","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/7495758","citation_count":26,"is_preprint":false},{"pmid":"2460248","id":"PMC_2460248","title":"The interaction of CD2 with its LFA-3 ligand expressed by autologous erythrocytes results in enhancement of B cell responses.","date":"1988","source":"Cellular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/2460248","citation_count":26,"is_preprint":false},{"pmid":"15110076","id":"PMC_15110076","title":"Immunotherapeutic effects of T11TS/S-LFA3 against nitrosocompound mediated neural genotoxicity.","date":"2004","source":"Toxicology letters","url":"https://pubmed.ncbi.nlm.nih.gov/15110076","citation_count":25,"is_preprint":false},{"pmid":"7519509","id":"PMC_7519509","title":"Expression of adhesion molecules CD11/CD18 (Leu-CAMs, beta 2-integrins), CD54 (ICAM-1) and CD58 (LFA-3) in B-chronic lymphocytic leukemia.","date":"1994","source":"Leukemia & lymphoma","url":"https://pubmed.ncbi.nlm.nih.gov/7519509","citation_count":25,"is_preprint":false},{"pmid":"9691200","id":"PMC_9691200","title":"MHC class II ligation induces CD58 (LFA-3)-mediated adhesion in human T cells.","date":"1998","source":"Experimental and clinical immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/9691200","citation_count":25,"is_preprint":false},{"pmid":"36516256","id":"PMC_36516256","title":"PAX5 epigenetically orchestrates CD58 transcription and modulates blinatumomab response in acute lymphoblastic leukemia.","date":"2022","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/36516256","citation_count":24,"is_preprint":false},{"pmid":"10470114","id":"PMC_10470114","title":"Differential expression of adhesion molecules (CD44, ICAM-1 and LFA-3) in cancer cells grown in monolayer or as multicellular spheroids.","date":"1999","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/10470114","citation_count":24,"is_preprint":false},{"pmid":"11157851","id":"PMC_11157851","title":"Effects of co-stimulation by CD58 on human T cell cytokine production: a selective cytokine pattern with induction of high IL-10 production.","date":"2001","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11157851","citation_count":23,"is_preprint":false},{"pmid":"38589927","id":"PMC_38589927","title":"HSPA4 upregulation induces immune evasion via ALKBH5/CD58 axis in gastric cancer.","date":"2024","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/38589927","citation_count":22,"is_preprint":false},{"pmid":"8907282","id":"PMC_8907282","title":"Expression of glycosyl-phosphatidylinositol-linked glycoproteins in blood cells from paroxysmal nocturnal haemoglobinuria patients: a flow cytometry study using CD55, CD58 and CD59 monoclonal antibodies.","date":"1996","source":"Leukemia & lymphoma","url":"https://pubmed.ncbi.nlm.nih.gov/8907282","citation_count":22,"is_preprint":false},{"pmid":"7584496","id":"PMC_7584496","title":"The effects of an immunomodulatory LFA3-IgG1 fusion protein on nonhuman primates.","date":"1994","source":"Therapeutic immunology","url":"https://pubmed.ncbi.nlm.nih.gov/7584496","citation_count":22,"is_preprint":false},{"pmid":"8550244","id":"PMC_8550244","title":"Expression of leukocyte cell adhesion molecules on gastric carcinomas: possible involvement of LFA-3 expression in the development of distant metastases.","date":"1995","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/8550244","citation_count":22,"is_preprint":false},{"pmid":"7504826","id":"PMC_7504826","title":"Human naive and memory T-helper cells display distinct adhesion properties to ICAM-1, LFA-3 and B7 molecules.","date":"1993","source":"Scandinavian journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/7504826","citation_count":22,"is_preprint":false},{"pmid":"29773030","id":"PMC_29773030","title":"T Cell Activation Pathways: B7, LFA-3, and ICAM-1 Shape Unique T Cell Profiles.","date":"2017","source":"Critical reviews in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/29773030","citation_count":21,"is_preprint":false},{"pmid":"17172599","id":"PMC_17172599","title":"Impact of salt bridges on the equilibrium binding and adhesion of human CD2 and CD58.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17172599","citation_count":21,"is_preprint":false},{"pmid":"8592403","id":"PMC_8592403","title":"Role of LFA-3, ICAM-1, and MHC class I on the sensitivity of human tumor cells to LAK cells.","date":"1996","source":"The Journal of surgical research","url":"https://pubmed.ncbi.nlm.nih.gov/8592403","citation_count":20,"is_preprint":false},{"pmid":"38635903","id":"PMC_38635903","title":"CD58 Alterations Govern Antitumor Immune Responses by Inducing PDL1 and IDO in Diffuse Large B-Cell Lymphoma.","date":"2024","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/38635903","citation_count":19,"is_preprint":false},{"pmid":"25143920","id":"PMC_25143920","title":"Immunoregulatory T cells, LFA-3 and HLA-DR in autoimmune thyroid diseases.","date":"2014","source":"Indian journal of endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/25143920","citation_count":19,"is_preprint":false},{"pmid":"23530775","id":"PMC_23530775","title":"Immunosuppression by co-stimulatory molecules: inhibition of CD2-CD48/CD58 interaction by peptides from CD2 to suppress progression of collagen-induced arthritis in mice.","date":"2013","source":"Chemical biology & drug design","url":"https://pubmed.ncbi.nlm.nih.gov/23530775","citation_count":19,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":50746,"output_tokens":9666,"usd":0.148614},"stage2":{"model":"claude-opus-4-6","input_tokens":13598,"output_tokens":4371,"usd":0.265898},"total_usd":0.414512,"stage1_batch_id":"msgbatch_011kfMfE81o6CTcyhVUqumuW","stage2_batch_id":"msgbatch_01DTputS6WNkH745x1nVSoBo","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1982,\n      \"finding\": \"LFA-3 (CD58) is a cell surface antigen (Mr ~60,000) expressed on both B and T lymphocytes that participates in CTL-target cell interaction; monoclonal antibodies blocking LFA-3 inhibit CTL-mediated killing, with anti-LFA-3 antibodies acting on target cells rather than effectors.\",\n      \"method\": \"Monoclonal antibody inhibition of CTL killing assay (51Cr-release), immunoprecipitation, NaDodSO4/PAGE, immunofluorescence flow cytometry\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — foundational discovery replicated in multiple subsequent studies; multiple orthogonal methods\",\n      \"pmids\": [\"6984191\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1983,\n      \"finding\": \"LFA-3 is a widely distributed antigen (Mr 60,000) present on both hematopoietic and nonhematopoietic tissues that functions on target cells to mediate CTL-mediated cytotoxicity and T cell proliferative responses; anti-LFA-3 MAb block by binding to target cells, not effectors.\",\n      \"method\": \"Monoclonal antibody blocking of CTL killing, MLR, and PHA proliferation assays\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — replicated across multiple functional assays, consistent with founding paper\",\n      \"pmids\": [\"6345670\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1984,\n      \"finding\": \"LFA-3 mediates CTL-target cell conjugate formation; antibodies to LFA-3 inhibit cytolysis by blocking CTL-target cell adhesion.\",\n      \"method\": \"CTL-target conjugate formation assay, 51Cr-release cytotoxicity assay with monoclonal antibody blocking\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct conjugate formation assay, replicated\",\n      \"pmids\": [\"6201533\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1987,\n      \"finding\": \"LFA-3 (CD58) is the direct cell-surface ligand for CD2; purified CD2 binds to human erythrocyte LFA-3 and mediates adhesion, and purified CD2 inhibits T cell rosetting with erythrocytes in an LFA-3-dependent manner.\",\n      \"method\": \"Radiolabeled (125I) CD2 binding to erythrocytes, rosetting inhibition assay, purified protein binding assays\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct binding with purified proteins, replicated independently\",\n      \"pmids\": [\"2951597\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1987,\n      \"finding\": \"LFA-3 cDNA encodes a phospholipid-linked (GPI-anchored) membrane protein whose extracellular domain shares significant homology with its receptor CD2, both being members of the immunoglobulin superfamily.\",\n      \"method\": \"cDNA cloning, sequence analysis, transient expression in mouse cells\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — cDNA cloning with sequence-based structural analysis, foundational paper >700 citations\",\n      \"pmids\": [\"3313052\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1987,\n      \"finding\": \"LFA-3 exists in two distinct membrane-anchored forms derived from different biosynthetic precursors: one anchored by a phosphatidylinositol glycan (GPI) moiety and one with a conventional transmembrane segment.\",\n      \"method\": \"Phosphatidylinositol-specific phospholipase C (PIPLC) treatment, biosynthetic labeling, biochemical fractionation\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — enzymatic treatment and biochemical fractionation demonstrating two isoforms; replicated in multiple subsequent studies\",\n      \"pmids\": [\"3313053\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1987,\n      \"finding\": \"LFA-3 on erythrocytes is attached to the membrane by a phosphatidylinositol glycolipid anchor; deficiency of LFA-3 on PNH erythrocytes correlates with phosphatidylinositol-anchored protein deficiency, and reconstitution of purified LFA-3 into PNH erythrocytes restores CD2 binding and rosetting activity.\",\n      \"method\": \"PIPLC treatment, 125I-CD2 binding, rosetting assay, reconstitution of purified protein into erythrocyte membranes\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstitution experiment plus enzymatic cleavage with functional readout\",\n      \"pmids\": [\"3309123\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1987,\n      \"finding\": \"CD2 and LFA-3 mediate thymocyte binding to thymic epithelial cells; anti-LFA-3 antibodies block binding when applied to thymic epithelial cells, while anti-CD2 antibodies block when applied to thymocytes, demonstrating LFA-3 on TE cells engages CD2 on thymocytes.\",\n      \"method\": \"Rosette formation inhibition assay with monoclonal antibodies, indirect immunofluorescence\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean dissection of receptor (CD2) vs. ligand (LFA-3) on defined cell populations, replicated\",\n      \"pmids\": [\"3098838\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1987,\n      \"finding\": \"LFA-3 expressed on human erythrocytes is the ligand for CD2; purified CD2 binds to erythrocyte LFA-3 and mediates T cell rosetting, with LFA-3 mAb blocking 125I-CD2 binding and CD2 blocking LFA-3 mAb binding (reciprocal competition).\",\n      \"method\": \"125I-CD2 binding competition, mAb blocking of rosetting, purified protein binding\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — purified protein binding with reciprocal competition demonstrating direct interaction\",\n      \"pmids\": [\"3102675\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1988,\n      \"finding\": \"LFA-3 can activate T cells via the CD2 complex; purified multimeric LFA-3 combined with anti-CD2 mAb induces intracellular calcium increases, phosphatidylinositol second messenger generation, and lymphokine secretion in Jurkat cells, but only when CD3/Ti complex is expressed and functionally intact.\",\n      \"method\": \"Intracellular calcium measurement, phosphatidylinositol hydrolysis assay, lymphokine secretion, CD3-deficient Jurkat mutants with TCR beta-chain reconstitution\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — signaling assays in mutant cell lines with genetic rescue, multiple readouts\",\n      \"pmids\": [\"2459194\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1988,\n      \"finding\": \"LFA-3 expressed on transfected L cells costimulates T cell and thymocyte proliferation via CD2; proliferation is inhibited by anti-CD2 or anti-LFA-3 mAbs and is associated with increased IL-2R expression.\",\n      \"method\": \"L cell transfection with LFA-3 genomic DNA, T cell proliferation assay, mAb blocking, IL-2R expression analysis\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — defined transfection system with specific mAb blocking, multiple readouts\",\n      \"pmids\": [\"2834437\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"Engagement of monocyte LFA-3 by immobilized anti-LFA-3 antibody or by purified CD2 (its physiologic receptor) triggers TNF-alpha and IL-1 beta release from monocytes, demonstrating that the CD2-LFA-3 receptor-ligand adhesion interaction can transmit signals inducing monokine secretion.\",\n      \"method\": \"Cytokine release assay (TNF-alpha, IL-1 beta) with immobilized antibodies and purified CD2 protein\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — purified CD2 used as physiologic ligand for LFA-3 with cytokine readout, specific functional mechanism demonstrated\",\n      \"pmids\": [\"1697984\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"Binding of anti-LFA-3 mAb (monovalent Fab' fragments sufficient) to thymic epithelial cell LFA-3 augments IL-1 alpha and IL-1 beta mRNA production and protein release, requiring new protein and RNA synthesis; this signals via LFA-3 engagement during thymocyte-TE cell contact.\",\n      \"method\": \"IL-1 release assay, Northern blot, cycloheximide/actinomycin D inhibition, Fab' fragment binding\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — monovalent Fab fragments rule out crosslinking artifact; multiple molecular readouts\",\n      \"pmids\": [\"1693636\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"Lateral mobility of GPI-anchored LFA-3 in the membrane enhances the rate of CD2-mediated cell adhesion strengthening compared to immobile transmembrane LFA-3; the GPI isoform supports more efficient adhesion at lower densities due to its ability to diffuse laterally and accumulate at the contact zone.\",\n      \"method\": \"Planar phospholipid bilayer reconstitution with GPI vs. transmembrane LFA-3 isoforms, static and laminar flow adhesion assays\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstitution of defined protein isoforms in bilayers with quantitative adhesion measurements\",\n      \"pmids\": [\"1717480\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"CD59, in addition to CD58, is a physiological ligand for CD2; CD59 binds CD2 at an overlapping but nonidentical binding site to CD58 on CD2, and antibodies to CD59 inhibit CD2-dependent T cell activation.\",\n      \"method\": \"In vitro binding assay with purified CD58 and CD59, CD2+ cell binding, T cell activation in murine hybridomas expressing human CD2, competition binding\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — purified protein binding assays with two complementary competition approaches\",\n      \"pmids\": [\"1377404\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"CD58 and CD59 molecules act synergistically (additively or synergistically) in mediating T cell adhesion and costimulating T cell activation; double transfectants expressing both CD58 and CD59 on CHO cells produce far more rosettes and T cell proliferation than either alone.\",\n      \"method\": \"CHO cell transfection with CD58 and/or CD59, rosette formation assay, T cell proliferation assay\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — defined transfectant system, two functional readouts; single lab\",\n      \"pmids\": [\"1370512\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"TCR stimulation or PMA treatment rapidly up-regulates CD2 avidity for CD58, requiring protein tyrosine kinase and protein kinase C activity, as well as the carboxyl-terminal asparagine of the CD2 cytoplasmic domain; cAMP elevation also up-regulates CD2 avidity through the same structural element.\",\n      \"method\": \"CD2+ cells binding to purified CD58, SRBC rosetting assay, inhibitors of PTK and PKC, CD2 cytoplasmic domain mutants\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — structure-function mutagenesis combined with pharmacological dissection in defined cell lines\",\n      \"pmids\": [\"7681075\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"The CD58-binding site on CD2 is a charged surface area (~770 Å2) on the AGFCC'C\\\" face of the CD2 adhesion domain, involving residues on the F strand (Lys-82, Tyr-86), C strand (Asp-32, Lys-34), C' strand (Gln-46), FG loop, CC' loop, and C'C\\\" loop, as identified by NMR-guided site-directed mutagenesis.\",\n      \"method\": \"Site-directed mutagenesis combined with NMR structural data, CD58 binding functional assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — NMR structure combined with site-directed mutagenesis and functional binding validation\",\n      \"pmids\": [\"7505442\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"The CD58 binding site on CD2 maps to the beta-sheet containing strands CC'C\\\"FG; key residues K34, E36 (C strand), R48, K49 (C' strand), K91, N92 (FG loop) are critical for CD2 interaction with both human and sheep CD58.\",\n      \"method\": \"Site-directed mutagenesis of CD2 domain 1 based on rat CD2 NMR solution structure, rosetting assay with human and sheep erythrocytes\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — structure-guided mutagenesis with functional rosetting readout\",\n      \"pmids\": [\"7688025\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"The CD58-binding surface on CD2 maps to the major beta-sheet face of CD58 (AGFCC'C\\\" sheet), involving residues on C strand (E25, K29, K30), CC' loop (K32, D33, K34), C' strand (E37), and G strand (K87); the interaction between CD2 and CD58 involves the major beta-sheet face of each adhesion domain.\",\n      \"method\": \"Site-directed mutagenesis of charged residues on CD58 predicted to be solvent-exposed, CD2 binding functional assays\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — structure-guided mutagenesis of both binding partners validated functionally\",\n      \"pmids\": [\"7525842\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"Ligation of B cell CD58 by CD2 (its natural T cell ligand) or by mAb provides an IL-4-dependent signal for IgE class switching and production, specifically inducing productive epsilon transcripts and IgE production in a pathway distinct from CD40-mediated isotype switching.\",\n      \"method\": \"Highly purified B cell cultures, IL-4 + anti-CD58 mAb, CD2-transfected murine T hybridoma coculture, CD40 Fc fusion protein competition, epsilon germ-line and productive transcript analysis\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — natural ligand (CD2-transfected cells) used, distinct pathway from CD40 demonstrated with multiple orthogonal methods\",\n      \"pmids\": [\"7515920\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"CD2-CD58 interaction visualized directly in the contact area between T lymphoblasts and planar bilayers containing fluorescently labeled LFA-3; LFA-3 accumulates at sites of contact with half-time ~15 min; the 2D Kd for CD2/LFA-3 interaction is ~21 molecules/μm², well below physiological densities of both molecules.\",\n      \"method\": \"Fluorescence microscopy of planar phospholipid bilayers with purified fluorescent LFA-3, two-dimensional affinity measurement, lateral diffusion analysis\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct visualization and quantitative 2D affinity measurement in defined reconstituted system\",\n      \"pmids\": [\"8636222\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"CD2-CD58 interaction optimizes T cell response to IL-12; monocyte CD58 engages T cell CD2, and CHO transfectants expressing CD58 at levels comparable to monocytes (but not CD48, a lower-avidity CD2 ligand) restore IL-12 responsiveness to APC-depleted T cells.\",\n      \"method\": \"CHO transfectants expressing CD58 or CD48, APC-depleted T cell cultures, IL-12 response assay, blocking antibodies\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — defined transfectant system with CD48 negative control distinguishing CD58-specific effect\",\n      \"pmids\": [\"8757306\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"CD58 (LFA-3) costimulation via CD2 preferentially induces NF-AT nuclear factor binding and IFN-gamma production in T cells; the NF-AT induced by LFA-3 is negatively regulated by B7-1 costimulation, revealing distinct transcriptional pathways for CD2-LFA-3 vs. CD28-B7-1 costimulation.\",\n      \"method\": \"Gel shift assays for NF-AT, AP-1, NF-kappaB; IL-2 promoter-luciferase reporter transfection; CHO transfectants with HLA-DR, B7-1, and/or LFA-3\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — gel shift and reporter assays in defined transfectant system; multiple transcription factors characterized\",\n      \"pmids\": [\"9032258\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"CD2-CD58 bond dynamics in contact areas are transient; fluorescence photobleaching recovery demonstrates rapid dissociation and partner exchange of CD2-CD58 bonds in the contact zone, consistent with the fast solution off-rate (>5 s-1).\",\n      \"method\": \"Fluorescence photobleaching recovery (FRAP) in T cell-planar bilayer contact zones with fluorescent CD58\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct real-time measurement of bond dynamics in reconstituted system\",\n      \"pmids\": [\"9188475\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Crystal structure of the CD2-binding domain of CD58 at 1.8 Å resolution reveals an Ig superfamily V-set topology sharing structural features with CD2; the highly acidic AGFCC'C\\\" beta-sheet surface of CD58 is the CD2-binding interface; charge complementarity rather than shape matching drives specificity.\",\n      \"method\": \"X-ray crystallography at 1.8 Å resolution of chimeric CD58, mutation mapping\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure with mutation mapping of binding interface\",\n      \"pmids\": [\"10200255\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"CD58 is constitutively expressed on the basolateral surface of intestinal epithelial cells (polarized expression) and functions as a costimulatory molecule for CD4+ T cell proliferation mediated by intestinal epithelial cells; CD58 blockade inhibits this costimulation, while CD80 and CD86 are absent.\",\n      \"method\": \"Flow cytometry, confocal microscopy, vectorial biotinylation, antibody blocking of T cell proliferation by IEC lines\",\n      \"journal\": \"Gastroenterology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct localization tied to functional consequence with specific mAb blocking\",\n      \"pmids\": [\"10220497\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"CD2 Tyr86 and CD58 Lys34 form the functional hot spot of the CD2-CD58 adhesion interface; Y86A mutation reduces CD58 binding affinity ~1000-fold while Y86F has virtually no effect (hydroxyl not required), and the CD2 D31/D32 residues orient CD58 K34 for hydrophobic contact with CD2 Y86.\",\n      \"method\": \"Isothermal titration calorimetry (ITC) of CD2 alanine mutants, CD2-CD58 crystal structure analysis\",\n      \"journal\": \"Journal of molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — quantitative ITC of single-residue mutants combined with structural analysis\",\n      \"pmids\": [\"11575926\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Endothelial cell costimulation of T cell activation via CD58-CD2 promotes lipid raft aggregation in T cells; CD2 crosslinking promotes raft aggregation and amplifies multiple TCR downstream pathways (AP-1, NF-AT, NF-kappaB) without targeting a single distinct pathway.\",\n      \"method\": \"AP-1/NF-AT/NF-kappaB luciferase reporter assays, IL-2 secretion assay, lipid raft aggregation assay with CD2 mAb blocking\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — lipid raft mechanism identified with CD2 mAb blocking; single lab, multiple pathways\",\n      \"pmids\": [\"11591762\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Coexpression of CD58 (or CD48) with ICAM-1 on target cells enables strong adhesion of resting NK cells even without cytokine activation; CD58 on targets engages receptors on resting NK cells to strengthen LFA-1-mediated adhesion.\",\n      \"method\": \"Drosophila cell expression system with defined ligand combinations, resting NK cell adhesion assays, inhibitors of src-family kinase and PI3K\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — defined reconstituted system with specific ligand combinations; clean dissection of receptor requirements\",\n      \"pmids\": [\"12496412\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"T cell activation increases CD2 cell surface number 1.5-fold and 2D affinity for CD58 by 2.5-fold; ligation of CD2 to CD58 decreases lateral mobility of CD2 (likely via cytoskeletal immobilization), collectively enhancing avidity and T cell-APC adhesion.\",\n      \"method\": \"Quantitative CD2 site measurements, 2D affinity measurement in contact zones, lateral mobility (FRAP) of CD2 on activated T cells\",\n      \"journal\": \"ACS chemical biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — quantitative biophysical measurements of 2D affinity and mobility in defined system\",\n      \"pmids\": [\"17168569\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"The protective rs2300747(G) allele in the CD58 locus is associated with a dose-dependent increase in CD58 mRNA expression and enhanced function of CD4+CD25high regulatory T cells via FoxP3 upregulation, suggesting CD58 engagement of CD2 promotes Treg function.\",\n      \"method\": \"Fine mapping and resequencing, mRNA expression quantification in LCL and PBMCs, FoxP3 expression analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — genetic-functional correlation with mRNA and Treg functional assay; mechanism partially defined\",\n      \"pmids\": [\"19237575\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Mutations and deletions inactivate the CD58 gene in 21% of DLBCL cases, abolishing cell-surface CD58 expression; CD58 genetic inactivation co-occurs with beta2-microglobulin inactivation, enabling escape from both T cell and NK cell immune surveillance.\",\n      \"method\": \"Sequencing of CD58 gene, deletion analysis, flow cytometry for protein expression, correlation with HLA-I loss\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct sequencing and protein expression analysis in primary tumor samples with functional immune evasion implication\",\n      \"pmids\": [\"22137796\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"CD2-CD58 interactions are required for activation of adaptive NKG2C+CD57+ NK cells in response to HCMV-infected fibroblasts; antibody blockade of CD2 or CD58 largely abolishes CD69/CD25/HLA-DR upregulation and IFN-gamma/TNF-alpha production specifically in adaptive NK cells, correlating with HCMV-induced upregulation of CD58 on infected cells.\",\n      \"method\": \"Co-culture of PBMCs with productively infected fibroblasts, blocking antibodies against CD2 and CD58, flow cytometry for activation markers, intracellular cytokine staining\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — specific blocking of both receptor (CD2) and ligand (CD58) with multiple functional readouts in physiologic infection model\",\n      \"pmids\": [\"27469079\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"EZH2 epigenetically silences CD58 expression in B-cell lymphoma via H3K27 trimethylation of the CD58 promoter; EZH2 inhibitors (EPZ6438, GSK126) relieve this repression, restore CD58 surface expression, and enhance T and NK cell IFN-gamma production against lymphoma cells.\",\n      \"method\": \"Epigenetic library screening, EZH2 inhibitor treatment, ChIP for H3K27me3 at CD58 promoter, flow cytometry for CD58 expression, T/NK cell IFN-gamma production co-culture assay\",\n      \"journal\": \"Molecular immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP directly demonstrates H3K27me3 at CD58 promoter; functional rescue upon EZH2 inhibition with multiple orthogonal methods\",\n      \"pmids\": [\"31962268\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"T-cell rosetting in Hodgkin lymphoma is established by CD2-CD58 interaction forming an immunological synapse; CD58 knockout or CD2 blockade reduces rosette formation and T-cell activation; T-cell activation additionally requires TCR-HLA-II interaction, as shown by CIITA knockout.\",\n      \"method\": \"HL cell line coculture rosetting model, CRISPR knockout of CIITA and CD58, CD2 blocking antibodies, proximity ligation assay in primary HL tissue\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — CRISPR KO of CD58 with functional rosetting and T cell activation readouts; validated in primary tissue by proximity ligation assay\",\n      \"pmids\": [\"32589698\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CD58 loss in tumor cells impairs CAR T cell function by inducing formation of suboptimal immunological synapses, reducing CAR T cell expansion, degranulation, cytokine secretion, and cytotoxicity; CD58 was identified as a top resistance gene via genome-wide CRISPR/Cas9 screen.\",\n      \"method\": \"Genome-wide CRISPR/Cas9 screen, CD58 KO validation in vitro and in vivo, immunological synapse imaging, degranulation and cytokine assays\",\n      \"journal\": \"Blood advances\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — unbiased genome-wide CRISPR screen followed by mechanistic validation with IS imaging and multiple functional readouts\",\n      \"pmids\": [\"35728062\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"PAX5 acts as a transcriptional activator of CD58 via a PAX5-driven enhancer at the CD58 locus; the PAX5 P80R mutation disrupts this enhancer, reducing CD58 expression and blinatumomab sensitivity in B-ALL.\",\n      \"method\": \"Genome-wide CRISPR screen for blinatumomab sensitivity, transcription factor CRISPR screen (1639 genes), genome editing of PAX5 P80R, ChIP/ATAC-seq for enhancer identification, patient blast validation\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — CRISPR screens plus genome editing with enhancer characterization and patient validation\",\n      \"pmids\": [\"36516256\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"CMTM6 is critical for CD58 protein stability; CMTM6 binding determines the balance between endosomal recycling and lysosomal degradation of CD58; CD58 and PD-L1 compete for CMTM6 binding such that loss of CD58 increases PD-L1 protein stabilization (and vice versa).\",\n      \"method\": \"CRISPR-Cas9 screens, proteomics screens, co-IP of CD58 and PD-L1 with CMTM6, endosomal recycling and lysosomal degradation assays, humanized mouse models, patient melanoma scRNA-seq\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — CRISPR screen with Co-IP validation; competition between CD58 and PD-L1 for CMTM6 mechanistically established with multiple orthogonal methods\",\n      \"pmids\": [\"37327789\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"CD58 inhibits JAK2/STAT1 pathway activity by activating the LYN/CD22/SHP1 axis; loss of CD58 in DLBCL leads to elevated JAK2/STAT1 activity, increased PDL1 and IDO expression, and immune evasion; combination of CD58-CD2 costimulatory signaling with anti-PDL1 or IDO inhibitor sensitizes CD58-deficient DLBCL to CAR T cell therapy.\",\n      \"method\": \"Co-IP, RNA-seq, whole-exome sequencing, scRNA-seq, DLBCL patient samples, CAR T cell co-culture functional assays, pathway inhibitor experiments\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — Co-IP and pathway analysis with functional validation; single study but multiple orthogonal approaches\",\n      \"pmids\": [\"38635903\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"HSPA4 upregulation increases ALKBH5 protein stability, which in turn decreases CD58 expression in gastric cancer cells through m6A methylation regulation; this reduces CD8+ T cell cytotoxicity and activates PD1/PDL1 axis.\",\n      \"method\": \"Co-immunoprecipitation, meRIP (m6A RNA immunoprecipitation), CD8+ T cell co-culture cytotoxicity assay, HSPA4 overexpression experiments\",\n      \"journal\": \"Journal of experimental & clinical cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — Co-IP and meRIP establishing mechanism; functional CD8+ T cell assay; single lab\",\n      \"pmids\": [\"38589927\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"A soluble form of CD58 (sCD58) is present in human serum, urine, and cell line supernatants; purified sCD58 binds to CD2-positive T cells and at high concentrations inhibits rosette formation, suggesting sCD58 can act as an immunosuppressive factor by competing with membrane-bound CD58 for CD2 binding.\",\n      \"method\": \"ELISA for CD58, gel filtration, SDS-PAGE/Western blot, rosette inhibition assay with purified sCD58\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — purified sCD58 used in functional rosette inhibition; biochemical characterization of soluble form\",\n      \"pmids\": [\"7693485\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"CD58/CD2 is the primary costimulatory pathway for CD28-negative CD8+ T cells; CD58 broadly expressed on APCs (including dendritic cells) engages CD2 to costimulate proliferation, cytokine production, and effector function of CD28-CD8+ T cells; blocking CD58 mAb greatly reduces responses to allogeneic DCs and viral antigens.\",\n      \"method\": \"mAb blocking of CD58 in CD28-CD8+ T cell stimulation assays with DCs, allogeneic and viral antigen responses, proliferation and cytokine measurements\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — defined T cell subset with specific mAb blocking, multiple functional readouts, DCs as physiological APCs\",\n      \"pmids\": [\"26041540\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CD58 (LFA-3) is a GPI-anchored or transmembrane Ig superfamily glycoprotein that functions as the primary cell-surface ligand for CD2 on T and NK cells; the CD2-CD58 interaction—characterized by a charged electrostatic interface between the AGFCC'C\\\" beta-sheets of both proteins (hot spot: CD2 Tyr86/CD58 Lys34)—drives T cell and NK cell adhesion, immunological synapse formation, and costimulatory signaling (including NF-AT activation, TCR signal amplification via lipid raft aggregation, IL-12 responsiveness, and IgE class switching), while CD58 protein stability is regulated by CMTM6-mediated endosomal recycling, its transcription is activated by PAX5 and repressed by EZH2-mediated H3K27 trimethylation, and loss of CD58 in tumors promotes immune evasion through impaired IS formation, increased PD-L1/IDO expression via LYN/CD22/SHP1-JAK2/STAT1 signaling, and competition with PD-L1 for CMTM6 binding.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"CD58 (LFA-3) is an immunoglobulin superfamily glycoprotein that serves as the principal ligand for CD2 on T cells and NK cells, mediating intercellular adhesion, immunological synapse formation, and costimulatory signaling essential for adaptive and innate immune responses [PMID:2951597, PMID:6984191, PMID:12496412]. CD58 exists as GPI-anchored and transmembrane isoforms, with the GPI form exhibiting enhanced lateral mobility that accelerates adhesion strengthening; the CD2–CD58 interaction is driven by charge complementarity between the AGFCC′C″ beta-sheet faces of both proteins, centered on a hot spot involving CD2 Tyr86 and CD58 Lys34 [PMID:3313053, PMID:10200255, PMID:11575926]. Engagement of CD58 costimulates T cell activation through NF-AT induction, lipid raft aggregation, and TCR signal amplification, promotes IL-12 responsiveness, drives IgE class switching on B cells, and triggers monokine release from monocytes and epithelial cells [PMID:9032258, PMID:11591762, PMID:8757306, PMID:7515920, PMID:1697984]. CD58 protein stability is regulated by CMTM6-mediated endosomal recycling in competition with PD-L1, its transcription is activated by PAX5 and repressed by EZH2-catalyzed H3K27 trimethylation, and loss of CD58—occurring in ~21% of DLBCLs—promotes immune evasion through impaired synapse formation and upregulation of PD-L1/IDO via derepressed JAK2/STAT1 signaling [PMID:37327789, PMID:36516256, PMID:31962268, PMID:22137796, PMID:38635903].\",\n  \"teleology\": [\n    {\n      \"year\": 1982,\n      \"claim\": \"Identification of LFA-3 (CD58) as a target-cell surface molecule required for CTL-mediated killing established its fundamental role in immune cell–cell interaction, answering whether a distinct non-MHC target-cell antigen participates in cytolysis.\",\n      \"evidence\": \"Monoclonal antibody blocking of CTL killing (51Cr-release), immunoprecipitation, and flow cytometry on B and T lymphocytes\",\n      \"pmids\": [\"6984191\", \"6345670\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the counter-receptor on effector cells unknown\", \"Molecular nature of LFA-3 undefined\", \"Mechanism of action (adhesion vs. signaling) unresolved\"]\n    },\n    {\n      \"year\": 1984,\n      \"claim\": \"Demonstration that anti-LFA-3 antibodies block CTL–target conjugate formation resolved that LFA-3 functions at the adhesion step rather than a post-adhesion lytic step.\",\n      \"evidence\": \"CTL–target conjugate formation assay with mAb blocking\",\n      \"pmids\": [\"6201533\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Counter-receptor identity still unknown\", \"Contribution of LFA-3 to non-CTL immune interactions untested\"]\n    },\n    {\n      \"year\": 1987,\n      \"claim\": \"Identification of CD2 as the direct receptor for CD58 using purified proteins, and molecular cloning revealing CD58 as an Ig superfamily member with both GPI-anchored and transmembrane isoforms, established the molecular framework for the CD2–CD58 adhesion system.\",\n      \"evidence\": \"Radiolabeled purified CD2 binding to erythrocyte LFA-3, cDNA cloning with sequence analysis, PIPLC enzymatic treatment distinguishing two anchor forms, reconstitution of purified LFA-3 into PNH erythrocytes restoring rosetting\",\n      \"pmids\": [\"2951597\", \"3313052\", \"3313053\", \"3309123\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of CD2–CD58 interaction unknown\", \"Functional significance of two isoforms unclear\", \"Signaling consequences of engagement undefined\"]\n    },\n    {\n      \"year\": 1988,\n      \"claim\": \"Demonstration that LFA-3 engagement of CD2 triggers calcium flux, phosphatidylinositol hydrolysis, and T cell proliferation—requiring an intact CD3/TCR complex—established CD58 as a bona fide costimulatory molecule rather than a simple adhesion factor.\",\n      \"evidence\": \"Signaling assays in Jurkat cells and CD3-deficient mutants with reconstitution; L cell transfectants driving T cell proliferation blocked by anti-CD2/anti-LFA-3 mAbs\",\n      \"pmids\": [\"2459194\", \"2834437\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream transcription factor targets uncharacterized\", \"Whether CD58 itself transduces signals (reverse signaling) unknown\"]\n    },\n    {\n      \"year\": 1990,\n      \"claim\": \"Discovery that CD2 engagement of LFA-3 on monocytes and thymic epithelial cells triggers TNF-α, IL-1α, and IL-1β release established bidirectional signaling through the CD2–CD58 axis—CD58 is not merely a passive ligand.\",\n      \"evidence\": \"Cytokine release assays with immobilized anti-LFA-3 and purified CD2 on monocytes; monovalent Fab′ fragment stimulation of thymic epithelial cells with actinomycin D/cycloheximide controls\",\n      \"pmids\": [\"1697984\", \"1693636\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"CD58 reverse signaling pathway components undefined\", \"Whether GPI-anchored isoform can signal remains unresolved\"]\n    },\n    {\n      \"year\": 1991,\n      \"claim\": \"Reconstitution of GPI-anchored versus transmembrane CD58 in planar bilayers showed that the GPI isoform's greater lateral mobility accelerates adhesion strengthening, providing a functional rationale for the two isoforms.\",\n      \"evidence\": \"Planar phospholipid bilayer reconstitution with purified isoforms, static and laminar flow adhesion assays\",\n      \"pmids\": [\"1717480\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo relevance of isoform-specific adhesion kinetics untested\", \"Regulation of isoform expression across tissues unknown\"]\n    },\n    {\n      \"year\": 1993,\n      \"claim\": \"NMR-guided and structure-based mutagenesis of both CD2 and CD58 mapped the binding interface to the AGFCC′C″ beta-sheet face of each domain, identifying key charged residues and establishing the electrostatic nature of the interaction.\",\n      \"evidence\": \"Site-directed mutagenesis guided by NMR structure of CD2, functional rosetting and binding assays for CD2 and CD58 mutants\",\n      \"pmids\": [\"7505442\", \"7688025\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No co-crystal structure yet\", \"Energetic contribution of individual residues not quantified\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Mapping the CD58-side interface and demonstrating that CD58 ligation on B cells induces IL-4-dependent IgE class switching (distinct from CD40 pathway) broadened CD58's role beyond T cell adhesion to include B cell isotype regulation.\",\n      \"evidence\": \"CD58 mutagenesis with CD2-binding assays; purified B cell cultures with anti-CD58 mAb or CD2-transfected hybridomas, epsilon transcript analysis\",\n      \"pmids\": [\"7525842\", \"7515920\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signaling pathway from CD58 to epsilon germline transcription unknown\", \"In vivo relevance of CD58-driven IgE switching unconfirmed\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Direct visualization of CD58 accumulation at T cell contact sites and measurement of a 2D Kd (~21 molecules/μm²) well below physiological densities, combined with the finding that CD58 optimizes T cell IL-12 responsiveness, established the biophysical basis for efficient synapse-like contact formation.\",\n      \"evidence\": \"Fluorescence microscopy of planar bilayers with fluorescent LFA-3; CHO transfectants expressing CD58 vs. CD48 in APC-depleted T cell IL-12 response assays\",\n      \"pmids\": [\"8636222\", \"8757306\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"True immunological synapse architecture with CD58 not yet characterized\", \"Whether CD58 segregates into distinct synapse zones unknown\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"The 1.8 Å crystal structure of the CD58 adhesion domain confirmed the V-set Ig topology and revealed that charge complementarity rather than shape matching drives CD2 binding specificity, resolving the structural basis of the interaction.\",\n      \"evidence\": \"X-ray crystallography of chimeric CD58 with mutation mapping\",\n      \"pmids\": [\"10200255\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Co-crystal of the CD2–CD58 complex not yet solved\", \"How charge complementarity translates to fast kinetics not mechanistically explained\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Identification of the CD2 Tyr86–CD58 Lys34 hot spot by ITC of alanine mutants quantified the energetic architecture of the interface and showed that CD58 costimulation promotes lipid raft aggregation as a mechanism of TCR signal amplification.\",\n      \"evidence\": \"Isothermal titration calorimetry of single-residue CD2 mutants; luciferase reporter assays for AP-1/NF-AT/NF-κB with lipid raft aggregation measurement on endothelial cell costimulation\",\n      \"pmids\": [\"11575926\", \"11591762\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Raft aggregation mechanism downstream of CD2 undefined\", \"Whether raft mechanism applies in vivo during APC encounter unknown\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Discovery that CD58 is genetically inactivated (mutations/deletions) in 21% of DLBCLs, co-occurring with β2-microglobulin loss, established CD58 as a tumor suppressor whose loss enables dual escape from T and NK cell surveillance.\",\n      \"evidence\": \"Sequencing and deletion analysis of CD58 in primary DLBCL samples, flow cytometry for surface expression, correlation with HLA-I loss\",\n      \"pmids\": [\"22137796\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional immune evasion not directly demonstrated in these tumors\", \"Whether CD58 loss is a driver or passenger event unresolved\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Establishing CD58–CD2 as the primary costimulatory pathway for CD28-negative CD8+ T cells explained how terminally differentiated effector cells maintain responsiveness in the absence of classical costimulation.\",\n      \"evidence\": \"mAb blocking of CD58 in DC-stimulated CD28⁻CD8⁺ T cell assays measuring proliferation, cytokines, and responses to viral antigens\",\n      \"pmids\": [\"26041540\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis for CD58 dominance over other CD2 ligands (CD48, CD59) in this context unexplored\", \"In vivo validation lacking\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Demonstration that EZH2 silences CD58 via H3K27me3 at its promoter, and that CD58 knockout disrupts T cell rosetting in Hodgkin lymphoma requiring both CD58-CD2 and TCR-HLA-II interactions, linked epigenetic regulation to immunological synapse integrity.\",\n      \"evidence\": \"ChIP for H3K27me3 at CD58 promoter with EZH2 inhibitor rescue; CRISPR KO of CD58 in HL cell lines with rosetting and proximity ligation in primary tissue\",\n      \"pmids\": [\"31962268\", \"32589698\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether EZH2-mediated silencing is specific to lymphoma or occurs broadly untested\", \"Precise structure of CD58-dependent immunological synapse undefined\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Genome-wide CRISPR screens identified CD58 as a top resistance gene for CAR T cell therapy and PAX5 as a transcriptional activator of CD58 via an enhancer element, mechanistically connecting transcription factor mutations to immune evasion.\",\n      \"evidence\": \"CRISPR screens for CAR T cell and blinatumomab sensitivity; CD58 KO with IS imaging and functional validation; PAX5 P80R genome editing with ChIP/ATAC-seq for enhancer characterization\",\n      \"pmids\": [\"35728062\", \"36516256\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether restoring CD58 expression rescues CAR T resistance in vivo untested\", \"Full catalog of transcription factors regulating CD58 incomplete\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Discovery that CMTM6 stabilizes CD58 through endosomal recycling, and that CD58 and PD-L1 compete for CMTM6 binding, revealed a post-translational regulatory axis linking loss of one immune molecule to gain of another inhibitory checkpoint.\",\n      \"evidence\": \"CRISPR screens, proteomics, co-IP of CD58/PD-L1 with CMTM6, endosomal recycling and lysosomal degradation assays, humanized mouse models, patient melanoma scRNA-seq\",\n      \"pmids\": [\"37327789\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of CMTM6 selectivity between CD58 and PD-L1 unknown\", \"Whether CMTM6 competition is therapeutically targetable untested\", \"Stoichiometry of the CD58–CMTM6 complex undefined\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Identification of the LYN/CD22/SHP1 axis as CD58's mechanism for suppressing JAK2/STAT1 signaling—and showing that CD58 loss derepresses PD-L1 and IDO expression—provided a signaling pathway linking CD58 to immune checkpoint regulation beyond simple adhesion.\",\n      \"evidence\": \"Co-IP, RNA-seq, whole-exome sequencing, scRNA-seq in DLBCL patient samples, CAR T cell co-culture with pathway inhibitors\",\n      \"pmids\": [\"38635903\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"LYN/CD22/SHP1 pathway downstream of CD58 established in single study\", \"Whether this signaling axis operates in non-lymphoma contexts untested\", \"Direct physical interaction between CD58 and LYN not demonstrated\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the atomic structure of the CD2–CD58 complex, the structural basis for CMTM6 selectivity between CD58 and PD-L1, whether therapeutic restoration of CD58 expression can overcome immune evasion in vivo, and the full signaling cascade downstream of CD58 reverse signaling in non-lymphoid cells.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No CD2–CD58 co-crystal structure\", \"CD58 reverse signaling pathway largely undefined\", \"Therapeutic strategies to restore CD58 not clinically validated\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098631\", \"supporting_discovery_ids\": [0, 2, 3, 13, 21, 29]},\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [3, 8, 9, 10, 22, 42]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 4, 5, 6, 26]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [41]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [9, 10, 22, 23, 33, 42]},\n      {\"term_id\": \"R-HSA-1500931\", \"supporting_discovery_ids\": [2, 7, 13, 21, 35, 36]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [23, 28, 39]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"CD2\",\n      \"CMTM6\",\n      \"PAX5\",\n      \"EZH2\",\n      \"CD59\",\n      \"LYN\",\n      \"ALKBH5\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}